US20230120597A1 - Co-agonists at glp-1 and gip receptors suitable for oral delivery - Google Patents

Co-agonists at glp-1 and gip receptors suitable for oral delivery Download PDF

Info

Publication number
US20230120597A1
US20230120597A1 US17/980,990 US202217980990A US2023120597A1 US 20230120597 A1 US20230120597 A1 US 20230120597A1 US 202217980990 A US202217980990 A US 202217980990A US 2023120597 A1 US2023120597 A1 US 2023120597A1
Authority
US
United States
Prior art keywords
amino
substituent
seq
compound
peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US17/980,990
Inventor
Patrick James Knerr
Brian Patrick Finan
Richard DiMarchi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS
Priority to US17/980,990 priority Critical patent/US20230120597A1/en
Publication of US20230120597A1 publication Critical patent/US20230120597A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons

Definitions

  • the present invention relates to novel compounds that are agonists of the glucagon-like peptide 1 (GLP-1) receptor and the glucose-dependent insulinotropic polypeptide (GIP) receptor with a protracted profile of action, suitable for oral administration to humans.
  • GLP-1 glucagon-like peptide 1
  • GIP glucose-dependent insulinotropic polypeptide
  • Glucagon-like peptide 1 is a gut enteroendocrine cell-derived hormone and one of two prominent endogenous physiological incretins. GLP-1 improves glycemic control by stimulating glucose-dependent insulin secretion in response to nutrients (glucose), inhibits glucagon secretion from the pancreatic alpha-cells, slows gastric emptying, and induces body weight loss primary by decreasing food consumption.
  • Glucose-dependent insulinotropic polypeptide GIP
  • GIP the other prominent incretin, improves glycemic control by stimulation of insulin secretion in response to nutrients (fat, glucose). Furthermore, GIP appears to improve plasma lipid profile and to stimulate calcium accumulation in bones.
  • GIP analogs have been shown to lower body weight and improve glycemic control, though comparatively less potent than GLP-1 analogs to lower body weight in rodent models (Mroz et al, Mol Metab, 2019, 20: 51-62). Moreover, GIP analogs induce body weight loss by additive/synergistic action with GLP-1 analogs in dual administration (Finan et al, Sci Transl Med, 2013, 5 (209): 209ra151; N ⁇ rregaard et al, Diabetes Obes Metab, 2018, 20 (1): 60-68), and as such represent suitable candidates for amplification of GLP-1-based pharmacology.
  • GIPR agonism can be recruited as a non-redundant partner to GLP-1R agonism as a single molecule co-agonist to amplify GLP-1 metabolic benefits, as has been shown in preclinical animal models, most notably body weight loss and glycemic control (Finan et al, Sci Transl Med, 2013, 5 (209): 209ra151; Coskun et al, Mol Metab, 2018, 18: 3-14). Two different peptides with high potency dual incretin receptor agonism have advanced to multi-dose clinical studies.
  • GLP-1 derivatives have been investigated clinically in the form of a once-daily tablet of semaglutide and the permeation enhancer sodium N-[8-(2-hydroxybenzoyl)amino]caprylate (SNAC) (Hedrington & Davis, Exp. Opin. Pharmacother. 2019, 20 (2): 133-141) to improve the very low typical exposure and bioavailability of GLP-1 derivatives following oral administration.
  • SNAC sodium N-[8-(2-hydroxybenzoyl)amino]caprylate
  • GLP-1/GIP co-agonists and their potential medical uses are described in several patent applications such as WO 2010/011439, WO 2013/164483, WO 2014/192284, WO 2015/067715, WO 2015/022420, WO 2015/086728, WO 2015/086729, WO 2016/111971, WO 2020/023386, U.S. Pat. No. 9,745,360, US 2014/162945, and US 2014/0357552.
  • Patent applications disclosing oral delivery of GLP-1 derivatives are described in e.g. WO 2011/080103, WO 2012/080471, WO 2013/189988, and WO 2019/149880.
  • the present invention relates to single molecule co-agonists comprising a peptide and a substituent, which react with both the human GLP-1 and GIP receptors with high potency and are suitable for daily oral administration to humans. This is achieved by the combination of certain peptide sequence variants with substituents via a single site acylation with a diacid based fatty acid.
  • An aspect of the invention relates to a peptide having the amino acid sequence
  • the invention relates to a peptide having the amino acid sequence
  • a further aspect of the invention relates to a method for preparing the GLP-1/GIP co-agonists described herein.
  • the invention relates to a pharmaceutical composition
  • a pharmaceutical composition comprising the GLP-1/GIP co-agonists compounds described herein.
  • a further aspect of the invention relates to medical use of the GLP-1/GIP co-agonists described herein.
  • the invention relates to use of the GLP-1/GIP co-agonists described herein for prevention or treatment of diabetes, obesity, and/or liver diseases.
  • the present invention relates to compounds that are GLP-1 receptor and the GIP receptor agonists, also referred to as GLP-1/GIP receptor co-agonists or simply co-agonists.
  • compound is used herein to refer to a molecular entity, and “compounds” may thus have different structural elements besides the minimum element defined for each compound or group of compounds. It follows that a compound may be a peptide or a derivative thereof, as long as the compound comprises the defined structural and/or functional elements.
  • compound is also meant to cover pharmaceutically relevant forms hereof, i.e. a compound as defined herein or a pharmaceutically acceptable salt, amide, or ester thereof.
  • analogue generally refers to a peptide, the sequence of which has one or more amino acid changes when compared to a reference amino acid sequence.
  • An “analogue” may also include amino acid elongations in the N-terminal and/or C-terminal positions and/or truncations in the N-terminal and/or C-terminal positions.
  • amino acid residues may be identified by their full name, their one-letter code, and/or their three-letter code. These three ways are fully equivalent.
  • Amino acids are molecules containing an amino group and a carboxylic acid group, and, optionally, one or more additional groups, often referred to as a side chain.
  • amino acid includes proteinogenic (or natural) amino acids (amongst those the 20 standard amino acids), as well as non-proteinogenic (or non-natural) amino acids.
  • Proteinogenic amino acids are those which are naturally incorporated into proteins.
  • the standard amino acids are those encoded by the genetic code.
  • Non-proteinogenic amino acids are either not found in proteins, or not produced by standard cellular machinery (e.g., they may have been subject to post-translational modification).
  • Non-limiting examples of non-proteinogenic amino acids are Aib ( ⁇ -aminoisobutyric acid, or 2-aminoisobutyric acid), norleucine, norvaline as well as the D-isomers of the proteinogenic amino acids.
  • the GLP-1/GIP receptor co-agonists described herein comprise or consist of a peptide and a substituent as defined below.
  • the peptide is a synthetic peptide created to optimize the activity at the GLP-1 and GIP receptors.
  • Compounds having a suitable receptor binding activity towards both the GLP-1 receptor and the GIP receptor have been identified as demonstrated in the examples herein.
  • the compounds further display an extended half-life gained by the substituent comprising a fatty acid group.
  • the carboxy terminus of a peptide holds a —COOH group.
  • the compounds may optionally include an amide group (C( ⁇ O)—NH 2 ) at the C-terminus, which is a naturally occurring modification substituting —OH with —NH 2 , such as seen with native Exendin-4.
  • the GLP-1/GIP receptor co-agonists described herein comprise a peptide and a substituent as defined below, in which the substituent is attached to the peptide backbone via an amino acid residue.
  • the amino acid sequence of the peptide is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N
  • the amino acid sequence of the peptide is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N
  • X 39 is absent. In one embodiment, X 38 and X 39 are absent. In one embodiment, X 37 , X 38 and X 39 are absent. In one embodiment, X 36 , X 37 , X 38 and X 39 are absent. In one embodiment, X 35 , X 36 , X 37 , X 38 and X 39 are absent. In one embodiment, X 34 , X 35 , X 36 , X 37 , X 38 and X 39 are absent. In one embodiment, X 33 , X 34 , X 35 , X 36 , X 37 , X 38 and X 39 are absent.
  • X 32 , X 33 , X 34 , X 35 , X 36 , X 37 , X 38 and X 39 are absent.
  • X 31 , X 32 , X 33 , X 34 , X 35 , X 36 , X 37 , X 38 and X 39 are absent.
  • X 30 , X 31 , X 32 , X 33 , X 34 , X 35 , X 36 , X 37 , X 38 and X 39 are absent.
  • X 32 X 33 X 34 X 35 is SSGA (SEQ ID NO.: 40).
  • X 32 X 33 X 34 X 35 is ESGA (SEQ ID NO.: 41). In further such embodiments, X 32 X 33 X 34 X 35 is SKGA (SEQ ID NO.: 42). In a further embodiment thereof, the peptide has an amide modification of the C-terminus.
  • amino acid sequence of the peptide is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoe
  • amino acid sequence of the peptide is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoe
  • amino acid sequence of the peptide is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoe
  • X 2 is Aib. In one embodiment, X 2 is A. In one embodiment, X 6 is F. In one embodiment, X 6 is V. In one embodiment, X 12 is I. In one embodiment, X 12 is Y. In one embodiment, X 13 is Y. In one embodiment, X 13 is A. In one embodiment, X 13 is L. In one embodiment, X 13 is I. In one embodiment, X 16 is K. In one embodiment, X 16 is E. In one embodiment, X 20 is Q. In one embodiment, X 20 is R. In one embodiment, X 20 is E. In one embodiment, X 20 is H. In one embodiment, X 21 is A. In one embodiment, X 21 is E.
  • X 23 is I. In one embodiment, X 23 is V. In one embodiment, X 24 is E. In one embodiment, X 24 is Q. In one embodiment, X 24 is N. In one embodiment, X 28 is A. In one embodiment, X 28 is R. In one embodiment, X 30 is G. In one embodiment, X 31 is P.
  • X 13 LEX 16 QAAX 20 X 21 FX 23 X 24 is selected from the group consisting of: LLEKQAAREFIN (SEQ ID NO.: 43), LLEKQAAREFIE (SEQ ID NO.: 44), LLEKQAAQEFIE (SEQ ID NO.:45) and LLEEQAAREFIE (SEQ ID NO.: 46).
  • X 13 LEX 16 QAAX 20 X 21 FX 23 X 24 is LLEKQAAREFIN (SEQ ID NO.: 43).
  • X 13 LEX 16 QAAX 20 X 21 FX 23 X 24 is LLEKQAAREFIE (SEQ ID NO.: 44).
  • X 13 LEX 16 QAAX 20 X 21 FX 23 X 24 is LLEKQAAQEFIE (SEQ ID NO.:45). In one embodiment, X 13 LEX 16 QAAX 20 X 21 FX 23 X 24 is LLEEQAAREFIE (SEQ ID NO.: 46).
  • amino acid sequence of the peptide is any one of SEQ ID NO.: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 33, 34 and 35.
  • the amino acid sequence of the peptide is any one of SEQ ID NO.: 10, 22 or 25.
  • amino acid sequence of the peptide is SEQ ID NO.: 25.
  • amino acid sequence of the peptide is any one of SEQ ID NO.: 18, 20, 23, 24.
  • amino acid sequence of the peptide is SEQ ID NO.: 33, 34 or 35.
  • the peptide has an amide modification of the C-terminus.
  • the GLP-1 and GIP receptor agonists comprise or consist of a substituent as defined below covalently linked to a peptide.
  • Such compounds may be referred to as derivatives of the peptide, as they are obtained by covalently linking a substituent to a peptide backbone.
  • An aspect of the invention relates to a compound comprising a peptide and a substituent; wherein the amino acid sequence of the peptide is:
  • X 2 is Aib or A
  • X 6 is F or V
  • X 12 is I or Y
  • X 13 is Y, A, L or I
  • X 16 is K or E
  • X 20 is Q, R, E, H
  • X 21 is A or E
  • X 23 is I or V
  • X 24 is E, Q or N
  • X 28 is A or R
  • X 30 is G or absent
  • X 31 is P or absent
  • X 32 is E, S or absent
  • X 33 is S, K or absent
  • X 34 is G or absent
  • X 35 is A or absent
  • X 36 is P or absent
  • X 37 is P or absent
  • X 38 is P or absent
  • X 39 is S or absent
  • An embodiment of the invention relates to a compound comprising a peptide and a substituent; wherein the amino acid sequence of the peptide is:
  • X 2 is Aib or A
  • X 6 is F or V
  • X 12 is I or Y
  • X 13 is Y, A, L or I
  • X 16 is K or E
  • X 20 is Q, R, E, H
  • X 21 is A or E
  • X 23 is I or V
  • X 24 is E, Q or N
  • X 28 is A or R
  • X 32 is E, S or absent
  • X 33 is S, K or absent
  • X 34 is G or absent
  • X 35 is A or absent
  • X 36 is P or absent
  • X 37 is P or absent
  • X 38 is P or absent
  • X 39 is S or absent
  • the peptide may be defined as described herein above.
  • the substituents described herein are attached to the peptide described herein via a lysine (K) residue in position 16 or 33.
  • the substituent is attached to the peptide via the epsilon-amino group of a Lysine (K) when said Lysine is included at position 16 or 33.
  • the substituent is a chemical structure covalently attached to the peptide that is capable of forming non-covalent complexes with plasma albumin, thereby promoting the circulation of the co-agonist with the blood stream, and also having the effect of protracting the time of action of the co-agonist, due to the fact that the complex of the co-agonist and albumin is only slowly removed by renal clearance.
  • the substituent comprises a fatty acid group.
  • the fatty acid group comprises a carbon chain which contains at least 8 consecutive —CH 2 — groups.
  • the fatty acid group comprises at least 10 consecutive —CH 2 — groups, such as least 12 consecutive —CH 2 — groups, at least 14 consecutive —CH 2 — groups, at least 16 consecutive —CH 2 — groups, or such as at least 18 consecutive —CH 2 — groups.
  • the fatty acid group comprises 8-20 consecutive —CH 2 — groups. In one embodiment, the fatty acid group comprises 10-18 consecutive —CH 2 — groups. In one embodiment, the fatty acid group comprises 12-18 consecutive —CH 2 — groups. In one embodiment, the fatty acid group comprises 14-18 consecutive —CH 2 — groups.
  • the substituent consists of several elements, such as a protractor element and one or more linker elements.
  • the term “protractor” is used to describe the fatty acid group which is the terminal part of the substituent responsible for extending half-life of the compound.
  • the protractor may be defined by:
  • Chem. 1 HOOC—(CH 2 ) n —CO—* wherein n is an integer in the range of 8-20, which may also be referred to as a C(n+2) diacid or as
  • n is an integer in the range of 8-20.
  • the substituent further comprises one or more linker elements.
  • the linker elements are linked to each other and the protractor by amide bonds and referred to as “Z” (see further below).
  • the number of linker elements may be at most 3, referred to as—Z1-Z2-Z3- where Z1 is connected with the protractor (Prot) and the last Z element is connected with the peptide, in which case the substituent may be referred to as Prot-Z1-Z2-Z3-.
  • the symbol*above thus indicates the attachment point to Z1, which when bound via an amide bond is a nitrogen.
  • Z1 is a bond (see below)
  • the symbol* indicates the attachment point to the nitrogen of the neighbouring Z element.
  • the substituent is defined by: Prot-Z1-Z2-Z3- wherein Prot- is selected from Chem1, Chem 1 b, and wherein n is an integer in the range of 16-20.
  • n 14, 15, 16, 17, 18, 19 or 20 in Chem. 1 or Chem. 1b.
  • n 14, 15, 16, 17, or 18 in Chem. 1 or Chem. 1 b.
  • n 14, 16, or 18 in Chem. 1 or Chem. 1 b.
  • n 16, 17, 18, 19 or 20 in Chem. 1 or Chem. 1 b.
  • n is 16, 18 or 20 in Chem. 1 or Chem. 1 b.
  • n is 18 or 20 in Chem. 1 or Chem. 1 b.
  • the protractor (Prot) is a C16 diacid or a C18 diacid.
  • the protractor (Prot) is a C18 diacid or a C20 diacid.
  • the protractor (Prot) is a C16, C18 diacid or a C20 diacid.
  • bond means a covalent bond.
  • linker element of Z1-Z3 is defined as a bond, it is equivalent to a situation wherein said linker element is absent.
  • the indication herein below that any of Z1-Z3 is a bond may also be read as any of Z1-Z3 being absent, so that the previous Z element is covalently linked to the next Z element that is not “a bond” (or absent).
  • the linker elements Z1-Z3 are individually selected from chemical moieties capable of forming amide bonds, including amino acid like moieties, such as Glu, ⁇ Glu (also termed gamma Glu or gGlu and defined by *—NH—CH—(COOH)—CH 2 —CH 2 —CO—*), ⁇ -Lys (also termed epsilon Lys or eLys and defined by *—NH—(CH 2 ) 4 —CH(NH 2 )—CO—*), Ser, Ala, Thr, Ado, Aeep and Aeeep and further moieties as described below.
  • amino acid like moieties such as Glu, ⁇ Glu (also termed gamma Glu or gGlu and defined by *—NH—CH—(COOH)—CH 2 —CH 2 —CO—*), ⁇ -Lys (also termed epsilon Lys or eLys and defined by *—NH—(CH 2 ) 4
  • Z1 is selected from ⁇ Glu, Glu, or a bond.
  • Z1 is ⁇ Glu
  • Z2 and Z3, are selected, independently of each other, from Glu, ⁇ -Lys, ⁇ Glu, Gly, Ser, Ala, Thr, Ado, Aeep, Aeeep and a bond.
  • Glu, Gly, Ser, Ala, Thr are amino acid residues well known in the art.
  • ⁇ -Lys is defined by Chem. 2: *—NH—(CH 2 ) 4 —CH(NH 2 )—CO—* which may also be described by
  • ⁇ Glu is defined by Chem. 3: *—NH—CH(COOH)—(CH 2 ) 2 —CO—* which may also be described by
  • Ado is defined by Chem. 4: *—NH—(CH 2 ) 2 —O—(CH 2 ) 2 —O—CH 2 —CO—* may also be referred to as 8-amino-3,6-dioxaoctanoic acid and which may also be described by
  • Aeep is defined by Chem. 5: *NH—CH 2 CH 2 OCH 2 CH 2 OCH 2 CH 2 CO*, which may also be described by
  • Aeeep is defined of Chem. 6: *NH—CH 2 CH 2 OCH 2 CH 2 OCH 2 CH 2 OCH 2 CH 2 OCH 2 CH 2 CO*, which may also be described by
  • Z2 and Z3 are selected, independently of each other, from Glu, ⁇ -Lys, ⁇ Glu, Gly, Ala, Ado, Aeep, Aeeep and a bond.
  • Z2 and Z3 are selected, independently of each other, from Glu, ⁇ -Lys, ⁇ Glu, Gly, Ala, Ado and a bond.
  • Z2 and Z3 are selected, independently of each other, from Glu, ⁇ -Lys, ⁇ Glu, Gly, Ado and a bond.
  • Z2 and Z3 are selected, independently of each other, from ⁇ -Lys, ⁇ Glu, Gly, Ado and a bond.
  • Z2 and Z3 are selected, independently of each other, from ⁇ -Lys, ⁇ Glu, Ado and a bond.
  • Z2 and Z3 are ⁇ -Lys or Ado.
  • Z2 and Z3 are Ado.
  • Z2 and Z3 are ⁇ -Lys.
  • the substituent is selected from substituents A, B, C, D, and E defined as below.
  • the substituent is selected from substituents A, B and C defined as follows:
  • the substituent is covalently attached to a lysine residue of the co-agonist by acylation, i.e. via an amide bond formed between a carboxylic acid group of the substituent and the epsilon-amino group of the lysine residue.
  • the substituent is covalently attached to a lysine residue in position 16 of the peptide backbone by acylation, i.e., via an amide bond formed between a carboxylic acid group of the substituent and the epsilon amino group of the lysine residue.
  • the substituent is covalently attached to a lysine residue in position 33 of the peptide backbone by acylation, i.e., via an amide bond formed between a carboxylic acid group of the substituent and the epsilon amino group of the lysine residue.
  • the co-agonists may exist in different stereoisomeric forms having the same molecular formula and sequence of bonded atoms but differing only in the three-dimensional orientation of their atoms in space.
  • the stereoisomerism of the exemplified co-agonists is indicated in the experimental section, in the names as well as the structures, using standard nomenclature. Unless otherwise stated the invention relates to all stereoisomeric forms of the embodied derivative.
  • the functional activity of the GLP-1/GIP receptor agonists as described herein can be tested in vitro as described herein in Example 2.
  • EO 50 half maximal effective concentration
  • the in vitro potency of compounds may thus be determined as described herein and the EC 50 determined.
  • the in vitro potency may, e.g., be determined in a medium containing membranes expressing the appropriate GLP-1 and/or GIP receptor, and/or in an assay with whole cells expressing the appropriate GLP-1 and/or GIP receptor.
  • the functional response of the human GLP-1 and/or GIP receptor may be measured in a reporter gene assay, e.g. in a stably transfected BHK cell line that expresses the human GLP-1 and/or GIP receptor and contains the DNA for the cAMP response element (CRE) coupled to a promoter and the gene for firefly luciferase (CRE luciferase).
  • CRE cAMP response element
  • Luciferase may be determined by adding luciferin, which by the enzyme is converted to oxyluciferin and produces bioluminescence, which is measured as a reporter of the in vitro potency.
  • luciferin which by the enzyme is converted to oxyluciferin and produces bioluminescence, which is measured as a reporter of the in vitro potency.
  • One example of such an assay is described in Example 2 as described herein.
  • the compounds may include a substituent designed to bind albumin, it is also important to note that the receptor activity may be affected by the presence or absence of human serum albumin (HSA) in the assay medium.
  • HSA human serum albumin
  • the compounds have potent in vitro effects to activate the human GLP-1 and GIP receptors.
  • the compounds are capable of activating the human GLP-1 and GIP receptors in vitro with an EC 50 of less than 20 pM in CRE luciferase reporter assays as described in Example 2 herein, when performed without HSA.
  • the compounds have an in vitro potency at the human GLP-1 and GIP receptors determined using the method of Example 2 corresponding to an EC 50 at or below 100 pM, more preferably below 50 pM, or most preferably below 20 pM.
  • the EC 50 in human GLP-1 and GIP receptors assays are both 1-25 pM, such as 1-20 pM, such as 1-15 pM or such as 1-10 pM.
  • the pharmacokinetic properties of the co-agonistic compounds may further be determined in vivo via pharmacokinetic (PK) studies.
  • Animal models such as the mouse, rat, monkey, dog, or pig may be used to perform this characterization.
  • animals are typically administered with a single dose of the drug, either intravenously, subcutaneously (s.c.), or orally (p.o.) in a relevant formulation.
  • Blood samples are drawn at predefined time points after dosing, and samples are analysed for concentration of drug with a relevant quantitative assay. Based on these measurements, time-plasma concentration profiles for the compound of study are plotted and a so-called non-compartmental pharmacokinetic analysis of the data is performed.
  • An important parameter is the terminal half-life as a long half-life indicates that less frequent administration of a compound may be possible.
  • the terminal half-life (t1 ⁇ 2) in vivo may be measured using a suitable model, such as after i.v. administration in minipigs described in Example 3; or after p.o administration in dogs described in Example 4.
  • the terminal half-life is half-life (t1 ⁇ 2) in vivo in minipigs after i.v. administration, e.g. as described in Example 3 herein.
  • the terminal half-life in minipigs is at least 24 hours, such as at least 30 hours, or such as at least 40 hours.
  • the terminal half-life is half-life (t1 ⁇ 2) in vivo in dogs after p.o. administration, e.g. as described in Example 4 herein.
  • the terminal half-life in dogs is at least 24 hours, such as at least 40 hours, or such as at least 50 hours.
  • the co-agonists as described herein are in the form of a pharmaceutically acceptable salt.
  • Salts are e.g. formed by a chemical reaction between a base and an acid, e.g.: 2NH 3 +H 2 SO 4 ⁇ (NH 4 ) 2 SO 4 .
  • the salt may be a basic salt, an acid salt, or it may be neither (i.e. a neutral salt).
  • Basic salts produce hydroxide ions and acid salts hydronium ions in water.
  • the salts of the co-agonists may be formed with added cations or anions between anionic or cationic groups, respectively. These groups may be situated in the peptide and/or in the substituent of the derivatives.
  • anionic groups include any free carboxylic acid groups in the substituent, if any, as well as in the peptide.
  • the peptide may include a free carboxylic acid group at the C-terminus, if present, as well as any free carboxylic acid group of internal acidic amino acid residues such as Asp and Glu.
  • Non-limiting examples of cationic groups include any free amino groups in the substituent, if any, as well as in the peptide.
  • the peptide may include a free amino group at the N-terminus, if present, as well as any free imidazole or amino group of internal basic amino acid residues such as His, Arg, and Lys.
  • the peptide or derivative is in the form of a pharmaceutically acceptable salt.
  • the co-agonists may for instance be produced by classical peptide synthesis, e.g. solid phase peptide synthesis using t-Boc or Fmoc chemistry or other well established techniques, see e.g. Greene and Wuts, “Protective Groups in Organic Synthesis”, John Wiley & Sons, 1999; Florencio Zaragoza Dörwald, “Organic Synthesis on Solid Phase”, Wiley-VCH Verlag GmbH, 2000; and “Fmoc Solid Phase Peptide Synthesis”, Edited by W. C. Chan and P. D. White, Oxford University Press, 2000.
  • the compounds may be produced by recombinant methods, e.g. by culturing a host cell containing a DNA sequence encoding the peptide sequence and capable of expressing the peptide, in a suitable nutrient medium under conditions permitting the expression of the peptide.
  • host cells suitable for expression of these peptides are: Escherichia coli, Saccharomyces cerevisiae , as well as mammalian BHK or CHO cell lines.
  • co-agonists that include non-natural amino acids and/or covalently attached substituents may be produced as described in the experimental part.
  • a further aspect of the invention relates to a method for preparing the peptides described herein.
  • a further aspect of the invention relates to a method for preparing the GLP-1/GIP co-agonists described herein.
  • the method for preparing a compound as described herein comprises a step of solid phase peptide synthesis.
  • the substituent may be built sequentially as part of the solid phase peptide synthesis or produced separately and attached via the lysine residue after peptide synthesis.
  • the compounds are produced by a two-step process whereby two peptide fragments are ligated after attachment of the substituent to one of the peptide fragments.
  • compositions comprising a GLP-1/GIP receptor co-agonist as described herein.
  • Compositions comprising the compound or a pharmaceutically acceptable salt hereof, and optionally one or more a pharmaceutically acceptable excipients may be prepared as is known in the art.
  • excipient broadly refers to any component other than the active therapeutic ingredient(s).
  • the excipient may be an inert substance, an inactive substance, and/or a not medicinally active substance.
  • the excipient may serve various purposes, e.g. as a carrier, vehicle, filler, binder, lubricant, glidant, disintegrant, flow control agent, crystallization inhibitor, solubilizer, stabilizer, coloring agent, flavoring agent, surfactant, emulsifier or combinations thereof and/or to improve administration, and/or to improve absorption of the active substance.
  • the amount of each excipient used may vary within ranges conventional in the art.
  • the pharmaceutical composition may be a solid formulation, e.g. a freeze-dried or spray-dried composition, which may be used as is, or whereto the physician or the patient adds solvents, and/or diluents prior to use.
  • the pharmaceutical composition may be a solid formulation consisting of the active ingredient, a salt of N-[8-(2-hydroxybenzoyl)amino]caprylate, and one or more further excipients as is known in the art, e.g. using any one or more of the formulations described in WO 2012/080471, WO 2013/189988, or WO 2019/149880.
  • the pharmaceutical composition is a liquid formulation, such as an aqueous formulation.
  • Liquid compositions suitable for injection, can be prepared using conventional techniques of the pharmaceutical industry which involve dissolving and mixing the ingredients as appropriate to give the desired end product.
  • a GLP-1/GIP co-agonist as described herein is dissolved in a suitable buffer at a suitable pH.
  • the composition may be sterilized, for example, by sterile filtration.
  • a further aspect of the invention relates to the use of GLP-1/GIP receptor co-agonist compounds as described herein as a medicament.
  • the compounds described herein are for use in the following medical treatments:
  • the compounds are for use in a method for prevention and/or treatment of diabetes and/or obesity.
  • the compounds are for use in a method for treatment of diabetes and/or obesity.
  • the compounds are for use in a method for treatment or prevention of type 2 diabetes.
  • the compounds are for use in a method for treatment of type 2 diabetes.
  • the compounds are for use in a method for treatment or prevention of obesity.
  • the compounds are for use in a method for treatment of obesity.
  • the compounds are for use in a method for weight management. In one embodiment, the compounds are for use in a method for reduction of appetite. In one embodiment, the compounds are for use in a method for reduction of food intake.
  • LLEKQAAREFIN SEQ ID NO.: 44
  • LLEKQAAREFIE LLEKQAAREFIE
  • SEQ ID NO.: 45 LLEKQAAQEFIE
  • SEQ ID NO.: 46 LLEEQAAREFIE
  • SPPS methods including methods for de-protection of amino acids, methods for cleaving the peptide from the resin, and for its purification), as well as methods for detecting and characterising the resulting peptide (LCMS methods) are described here below.
  • Resins employed for the preparation of C-terminal peptide amides were H-Rink Amide-ChemMatrix resin (loading e.g. 0.5 mmol/g).
  • the Fmoc-protected amino acid derivatives used were the standard recommended: Fmoc-Ala-OH, Fmoc-Arg(Pbf)-OH, Fmoc-Asn(Trt)-OH, Fmoc-Asp(OtBu)-OH, Fmoc-Cys(Trt)-OH, Fmoc-Gln(Trt)-OH, Fmoc-Glu(OtBu)-OH, Fmoc-Gly-OH, Fmoc-His(Trt)-OH, Fmoc-Ile-OH, Fmoc-Leu-OH, Fmoc-Lys(Boc)-OH, Fmoc-Met-OH, Fmoc-Phe-
  • N-terminal amino acid was Boc protected at the alpha-amino group, either by using a reagent with the Boc group pre-installed (e.g. Boc-Tyr(tBu)-OH for peptides with Tyr at the N-terminus) or by exchanging the N-terminal Fmoc protective group for the Boc protective group after installation of the amino acid at the peptide N-terminus.
  • Boc-Tyr(tBu)-OH for peptides with Tyr at the N-terminus
  • Fmoc protective group for the Boc protective group after installation of the amino acid at the peptide N-terminus.
  • the following suitably protected building blocks such as but not limited to Fmoc-8-amino-3,6-dioxaoctanoic acid (Fmoc-Ado-OH), Boc-Lys(Fmoc)-OH, Fmoc-Glu-OtBu, hexadecanedioic acid mono-tert-butyl ester, octadecanedioic acid mono-tert-butyl ester, nonadecanedioic acid mono-tert-butyl ester, eicosanedioic acid mono-tert-butyl ester, tetradecanedioic acid mono-tert-butyl ester, or 4-(9-carboxynonyloxy) benzoic acid tert-butyl ester were used. All operations stated below were performed within a 0.1-0.2 mmol synthesis scale range.
  • SPPS was performed using Fmoc based chemistry on a Protein Technologies SymphonyX solid phase peptide synthesizer, using the manufacturer supplied protocols with minor modifications. Mixing was accomplished by occasional bubbling with nitrogen.
  • the step-wise assembly was performed using the following steps: 1) pre-swelling of resin in DMF; 2) Fmoc-deprotection by the use of 20% (v/v) piperidine in DMF for two treatments of 10 min each; 3) washes with DMF to remove piperidine; 4) coupling of Fmoc-amino acid by the addition of Fmoc-amino acid (12 equiv) and Oxyma Pure® (12 equiv) as a 0.6 M solution each in DMF, followed by addition of DIC (12 equiv) as a 1.2 M solution in DMF, followed by the addition of DMF to reduce the final concentration of each component to 0.3 M, then mixing for 0.5-4 h; 4) washes with DMF to remove excess reagents; 5) final was
  • the protected peptidyl resin was synthesized according to the Fmoc strategy on an Applied Biosystems 431A solid-phase peptide synthesizer using the manufacturer supplied general Fmoc protocols. Mixing was accomplished by vortexing and occasional bubbling with nitrogen.
  • the step-wise assembly was done using the following steps: 1) activation of Fmoc-amino acid by dissolution of solid Fmoc-acid acid (10 equiv) in CI-HOBt (10 equiv) as a 1 M solution in NMP, then addition of DIC (10 equiv) as a 1 M solution in NMP, then mixing simultaneous to steps 2-3; 2) Fmoc-deprotection by the use of 20% (v/v) piperidine in NMP for one treatment of 3 min then a second treatment of 15 min; 3) washes with NMP to remove piperidine; 4) addition of activated Fmoc-amino acid solution to resin, then mixing for 45-90 min; 4) washes with NMP to remove excess reagents; 5) final washes with DCM at the completion of the assembly.
  • the standard protected amino acid derivatives listed above were supplied in pre-weighed cartridges (from e.g. Midwest Biotech), and non-standard derivatives were weighed by hand.
  • Some amino acids such as, but not limited to, those following a sterically hindered amino acid (e.g. Aib) were “double coupled” to ensure reaction completion, meaning that after the first coupling (e.g. 45 min) the resin is drained, more reagents are added (Fmoc-amino acid, DIC, CI-HOBt), and the mixture allowed to react again (e.g. 45 min).
  • SPPS was performed using Fmoc based chemistry on a PreludeX solid phase peptide synthesizer, using the manufacturer supplied protocols with minor modifications. Mixing was accomplished by shaking at 350 rpm and occasional bubbling with nitrogen.
  • the step-wise assembly was performed using the following steps: 1) pre-swelling of resin in DMF; 2) Fmoc-deprotection by the use of 20% (v/v) piperidine in DMF for one treatment of 3 min at 70° C.; 3) washes with DMF to remove piperidine; 4) coupling of Fmoc-amino acid by the addition of Fmoc-amino acid (12 equiv) and Oxyma Pure® (12 equiv) as a 0.4 M solution each in DMF, followed by addition of DIC (12 equiv) as a 1.2 M solution in DMF, then mixing for 5 min at 70° C.; 4) washes with DMF to remove excess reagents; 5) final washes with DCM at the completion
  • N-epsilon-lysine protection Mtt protection group was removed by washing the resin with 30% HFIP in DCM for two treatments of 45 min each, following by washing with DCM and DMF.
  • Acylation was performed on a Protein Technologies SymphonyX solid phase peptide synthesizer using the protocols described in method SPPS_A using stepwise addition of building blocks, such as, but not limited to, Boc-Lys(Fmoc)-OH, Fmoc-8-amino-3,6-dioxaoctanoic acid, Fmoc-Glu-OtBu, hexadecanedioic acid mono-tert-butyl ester, octadecanedioic acid mono-tert-butyl ester, and eicosanedioic acid mono-tert-butyl ester.
  • building blocks such as, but not limited to, Boc-Lys(Fmoc)-OH, Fmoc-8-amino
  • N-epsilon-lysine protection Mtt protection group was removed by washing the resin with 30% HFIP in DCM for two treatments of 45 min each, following by washing with DCM and DMF.
  • Acylation was performed on an Applied Biosystems 431A solid-phase peptide synthesizer using the protocols described in method SPPS_B using stepwise addition of building blocks, such as, but not limited to, Boc-Lys(Fmoc)-OH, Fmoc-8-amino-3,6-dioxaoctanoic acid, Fmoc-Glu-OtBu, hexadecanedioic acid mono-tert-butyl ester, octadecanedioic acid mono-tert-butyl ester, and eicosanedioic acid mono-tert-butyl ester.
  • building blocks such as, but not limited to, Boc-Lys(Fmoc)-OH, Fmoc-8
  • N-epsilon-lysine protection Mtt protection group was removed by washing the resin with 30% HFIP in DCM for two treatments of 45 min each, following by washing with DCM and DMF.
  • Acylation was performed on a Protein Technologies PreludeX solid phase peptide synthesizer using the protocols described in method SPPS_C using stepwise addition of building blocks, such as, but are not limited to, Boc-Lys(Fmoc)-OH, Fmoc-8-amino-3,6-dioxaoctanoic acid, Fmoc-Glu-OtBu, hexadecanedioic acid mono-tert-butyl ester, octadecanedioic acid mono-tert-butyl ester, and eicosanedioic acid mono-tert-butyl ester.
  • building blocks such as, but are not limited to, Boc-Lys(Fmoc)-OH, Fmoc-8-
  • the peptidyl resin was washed with DCM and dried, then treated with TFA/water/TIS (95:2.5:2.5 v/v/v) for approximately 2 h, followed by precipitation with diethyl ether.
  • the precipitate was washed with diethyl ether, dissolved in a suitable solvent (e.g. 2:1 water/MeCN), and let stand until all labile adducts decomposed.
  • Purification was performed by reversed-phase preparative HPLC (Waters 2545 binary gradient module, Waters 2489 UV/Visible detector, Waters fraction collector III) on a Phenomenex Luna C8(2) column (10 ⁇ M particle size, 100 ⁇ pore size, 250 ⁇ 21.2 mm dimensions).
  • the freeze-dried peptide isolated from method CP_A was dissolved to 5-20 mg/mL in an appropriate aqueous buffer (e.g. 4:1 water/MeCN, 0.2 M sodium acetate) and adjusted to pH 7-8 with 1 M NaOH if necessary to achieve full solubility.
  • the buffered solutions containing the peptide were salt-exchanged using a Sep-Pak C18 cartridge (0.5-2 g): The cartridge was first equilibrated with 4 column volumes of isopropanol, then 4 column volumes of MeCN, then 8 column volumes of water. The peptide solution was applied to the cartridge, and the flow through was reapplied to ensure complete retention of peptide.
  • the cartridge was washed with 4 column volumes of water, then 10 column volumes of a buffer solution (e.g. pH 7.5) containing such as, but not limited to, NaHCO 3 , NaOAc, or Na 2 HPO 4 .
  • a buffer solution e.g. pH 7.5
  • the column was washed with 4 column volumes of water, and the peptide was eluted with 5-10 column volumes of 50-80% MeCN in water.
  • the peptide-containing eluent was freeze-dried to afford the peptide sodium salt as a white solid, which was used as such.
  • LCMS_A was performed on a setup consisting of an Agilent 1260 Infinity series HPLC system and an Agilent Technologies 6120 Quadrupole MS. Eluents: A: 0.05% TFA in water; B: 0.05% TFA in 9:1 MeCN/water.
  • LCMS_B was performed on a setup consisting of an Agilent 1260 Infinity series HPLC system and an Agilent Technologies 6120 Quadrupole MS. Eluents: A: 0.05% TFA in water; B: 0.05% TFA in 9:1 MeCN/water.
  • the compounds are in the following described using single letter amino acid codes, except for Aib.
  • the substituent is included after the lysine (K) residue to which it is attached.
  • Y-Aib-EGTFTSDYSIILE-K [2-[2-[[2-[2-[2-[[(4S)-4-carboxy-4-(17-carboxyheptadecanoylamino)butanoyl]amino]ethoxy]ethoxy]acetyl]amino]ethoxy]ethoxy] acetyl]-QAAREFINWLLAGGPSSGAPPPS-OH
  • the purpose of this example is to test the functional activity, or potency, of the compounds in vitro at the human GLP-1 and GIP receptors.
  • the in vitro functional potency is the measure of target receptor activation in a whole cell assay.
  • the potencies of derivatives of Example 1 were determined as described below. Human GLP-1(7-37) and human GIP were included in appropriate assays for comparison.
  • In vitro functional potency was determined by measuring the response of the target receptor in a reporter gene assay in individual cell lines.
  • the assay was performed in stably transfected BHK cell lines that expresses one of the following G-protein coupled receptors: human GLP-1 receptor or human GIP receptor; and where each cell line contains the DNA for the cAMP response element (CRE) coupled to a promoter and the gene for firefly luciferase (CRE luciferase).
  • CRE cAMP response element
  • luciferase substrate luciferin
  • luciferin luciferase substrate
  • the cells lines used in these assays were BHK cells with BHKTS13 as a parent cell line.
  • the cell lines were derived from a clone containing the CRE luciferase element and were established by further transfection with the respective human receptor to obtain the relevant cell line: BHK CRE luc2P hGLP-1R or BHK CRE luc2P hGIPR.
  • the cells were cultured at 37° C. with 5% CO 2 in Cell Culture Medium. They were aliquoted and stored in liquid nitrogen. The cells were kept in continuous culture and were seeded out the day before each assay.
  • Pluronic F-68 10% (Gibco 2404), human serum albumin (HSA; Sigma A9511), 10% fetal bovine serum (FBS; Invitrogen 16140-071), chicken egg white ovalbumin (Sigma A5503), DMEM w/o phenol red (Gibco 21063-029), DMEM (Gibco 12430-054), 1 M Hepes (Gibco 15630), Glutamax 100 ⁇ (Gibco 35050), G418 (Invitrogen 10131-027), hygromycin (Invitrogen 10687-010), and steadylite plus (PerkinElmer 6016757).
  • Pluronic F-68 10% (Gibco 2404), human serum albumin (HSA; Sigma A9511), 10% fetal bovine serum (FBS; Invitrogen 16140-071), chicken egg white ovalbumin (Sigma A5503), DMEM w/o phenol red (Gibco 21063-029), DMEM (Gibco 12
  • GLP-1R Cell Culture Medium consisted of DMEM medium with 10% FBS, 500 ⁇ g/mL G418, and 300 ⁇ g/mL hygromycin.
  • GIPR Cell Culture Medium consisted of DMEM medium with 10% FBS, 400 ⁇ g/mL G418, and 300 ⁇ g/mL hygromycin.
  • Assay Buffer consisted of DMEM w/o phenol red, 10 mM Hepes, 1 ⁇ Glutamax. 1% ovalbumin, and 0.1% Pluronic F-68 with the addition of HSA at twice the final assay concentration. The Assay Buffer was mixed 1:1 with an equal volume of the test compound in Assay Buffer to give the final assay concentration of HSA.
  • the data from the microtiter plate reader was first regressed in an Excel in order to calculate the x-axis, log scale concentrations based on the individual test compound's stock concentration and the dilutions of the assay. This data was then transferred to GraphPad Prism software for graphing and statistical analysis. The software performs a non-linear regression (log(agonist) vs response). EC 50 values which were calculated by the software and reported in pM are shown in Tables 1-3 below. A minimum of two replicates was measured for each sample. The reported values are averages of the replicates.
  • the compounds of the present invention display potent functional activation of the human GLP-1R and human GIPR receptors under the given conditions. Alteration of the peptide and/or the substituent resulted in unpredictable changes in the measured potencies at each of the two receptors, as well as the ratio of potencies between the two receptors, for each compound.
  • the purpose of this example is to determine the half-life in vivo of the derivatives of the present invention after i.v. administration to minipigs, i.e. the prolongation of their time in the body and thereby their time of action. This is done in a pharmacokinetic (PK) study, where the terminal half-life of the derivative in question is determined.
  • terminal half-life is generally meant the period of time it takes to halve a certain plasma concentration, measured after the initial distribution phase.
  • mice Female Gottingen minipigs were obtained from Ellegaard Gottingen Minipigs (Dalmose, Denmark) approximately 7-14 months of age and weighing from approximately 16-35 kg were used in the studies. The minipigs were housed individually and fed restrictedly once daily with SDS minipig diet (Special Diets Services, Essex, UK).
  • the animals were fasted for approximately 18 hours before dosing and from 0 to 4 hours after dosing but had ad libitum access to water during the whole period.
  • the sodium salts of compounds of Examples 1 were dissolved to a concentration of 20-40 nmol/mL in a buffer containing 0.007% polysorbate 20, 50 mM sodium phosphate, 70 mM sodium chloride, pH 7.4.
  • Intravenous injections (the volume corresponding to usually 1.5-2 nmol/kg, for example 0.1 mL/kg) of the compounds were given through one catheter, and blood was sampled at predefined time points for up to 14 days post dosing (preferably through the other catheter). Blood samples (for example 0.8 mL) were collected in 8 mM EDTA buffer and then centrifuged at 4° C. and 1942 g for 10 minutes.
  • the tested compounds of the present invention have very long half-lives as compared to the half-lives of hGLP-1 and hGIP measured in man to be approximately 2-4 min and 5-7 min, respectively (Meier et al., Diabetes, 2004, 53(3): 654-662).
  • the measured half-lives in minipigs predict half-lives in humans sufficient for at least once-weekly administration via liquid injection or at least once-daily administration via oral tablet.
  • alterations to the peptide sequence led to appreciable differences in half-lives between co-agonists tested herein even though these co-agonists incorporate the same substituent.
  • the purpose of this example is to determine the half-life and plasma exposure in vivo of the compounds of the present invention after p.o. administration to beagle dogs, i.e. the terminal half-life and concentration of test substance that reaches circulation with time. This is done in a pharmacokinetic (PK) study, where these parameters of the compound in question are determined.
  • terminal half-life is generally meant the period of time it takes to halve a certain plasma concentration, measured after the initial distribution phase.
  • Tablet compositions comprising the test substance and SNAC (sodium N-(8-(2-hydroxybenzoyl)amino)caprylate) were prepared according to methods known to the person skilled in the art by mixing test substance with roller compacted SNAC and magnesium stearate as e.g. described in WO 2019/149880.
  • the amount of SNAC in the tablet composition was 100-300 mg
  • the amount of magnesium stearate in the tablet composition was 7.7 mg
  • the target amount of each test substance in the tablet composition was 3-4 mg.
  • the dogs were dosed in a fasting state.
  • the dogs were group housed in pens (12 hours light: 12 hours dark), and fed individually and restrictedly once daily with Royal Canin Medium Adult dog food (Royal Canin Products, China Branch, or Brogaarden A/S, Denmark).
  • the dogs were used for repeated PK studies with a suitable wash-out period between successive dosing. An appropriate acclimatization period was given prior to initiation of the first PK study. All handling, dosing, and blood sampling of the animals were performed by trained and skilled staff.
  • the dogs were fasted overnight and from 0 to 4 hours after dosing.
  • the dogs were restricted to water 1 hour before dosing until 4 hours after dosing, but otherwise had ad libitum access to water during the whole period.
  • compositions were administered by a single oral dosing to the dogs in groups of 6-8 dogs.
  • the tablets were administered in the following manner: 10 min prior to tablet administration, the dogs may be dosed subcutaneously with approximately 3 nmol/kg of SEQ ID NO: 48, then tablets were placed in the back of the mouth of the dog to prevent chewing. The mouth was then closed, and 10 mL of tap water was given by syringe or gavage to facilitate swallowing of the tablet.
  • One blood sample was drawn before dosing, and additional samples were drawn at predefined time points after dosing for up to 240 hours, such as up to 10 hours, to adequately cover the full plasma concentration-time absorption profile of the test substance.
  • For each blood sample time point approximately 0.8 mL of whole blood was collected in a 1.5 mL EDTA-coated tube, which was gently turned to mix the sample with EDTA.
  • Blood samples were collected in EDTA buffer (8 mM) and then centrifuged at 4° C. 2000 g for 10 minutes. Plasma was pipetted into Micronic tubes on dry ice, and kept at ⁇ 20° C. or lower until analysis.
  • Blood samples were taken as appropriate, for example from a venflon in the cephalic vein in the front leg for the first 2 hours and then with syringe from the jugular vein for the rest of the time points. The first few drops were allowed to drain from the venflon to avoid heparin saline from the venflon in the sample.
  • the plasma was analysed for test substance using LC-MS (Liquid Chromatography-Mass Spectrometry) as known to the person skilled in the art.
  • the system consisted of either: a Thermo Fisher QExactive mass spectrometer equipped with a 10-valve interface module TurboFlow system, CTC HTS PAL autosampler, Accela 1250 pumps, and Hot Pocket column oven; or a Thermo Fisher QExactive Plus mass spectrometer equipped with a valve interface module TurboFlow system, TriPlus RSI autosampler, Dionex UltiMate 3000 pumps, and Hot Pocket column oven.
  • RP-HPLC separation was achieved using a linear gradient of 1:1 acetonitrile/methanol in 1% aqueous formic acid using either: a Phenomenex Onyx Monolithic C18 column (50 ⁇ 2.0 mm) and a flow rate of 0.8 mL/min at 30° C.; or an Agilent Poroshell 120 SB-C18 column (50 ⁇ 2.1 mm, 2.7 ⁇ m) at a flow rate of 0.4 mL/min at 60° C.
  • the mass spectrometer was operated in either positive ionization SIM mode or positive ionization PRM mode.
  • a plasma concentration-time profile was analysed by a non-compartmental model in Pharsight Phoenix WinNonLin ver. 6.4 software or other relevant software for PK analysis, and the resulting terminal half-life (t 1/2 ), maximum plasma concentration per dose (C max /D), time for maximum plasma concentration (t max ), and area under the curve to infinity per dose (AUC/D) were determined.
  • Summary statistics of pharmacokinetic results were presented as median (for t max ), hormonic mean (t 1/2 ), or arithmetic mean (C max , AUC).
  • the tested compounds of the present invention demonstrate oral bioavailability in this model, as concentrations of the compound in plasma were detected (C max /D>0 and AUC/D>0) following oral administration. Furthermore, the tested compounds of the present invention further have very long half-lives as compared to the half-lives of hGLP-1 and hGIP measured in man to be approximately 2-4 min and 5-7 min, respectively (Meier et al., Diabetes, 2004, 53(3): 654-662). Alterations to the peptide sequence led to unpredictable differences in t 1/2 , C max /D and AUC/D between co-agonists even when the same substituent was incorporated. Additionally, an unexpectedly large difference in t 1/2 was observed depending on the position of the amino acid attached to the substituent, such as eg., Compound No. 43 compared to all other compounds tested herein.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Toxicology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Peptide co-agonists of the human GLP-1 and GIP receptors suitable for oral delivery, including long-acting derivatives, and their medical use in treatment and/or prevention of obesity, diabetes, and/or liver diseases are described.

Description

    CROSS-REFERENCE TO RELATED APPLICATIONS
  • This application is a continuation of U.S. application Ser. No. 17/574,079, filed on Jan. 12, 2022, which is a continuation of International Application No. PCT/EP2021/070485, filed Jul. 22, 2021 and claims priority under 35 U.S.C. § 119 to U.S. Provisional Application 63/156,988, filed Mar. 5, 2021, U.S. Provisional Application 63/055,026, filed Jul. 22, 2020 and European Patent Application 20192414.9, filed Aug. 24, 2020; the contents of which are incorporated herein by reference.
    • TECHNICAL FIELD OF THE INVENTION
  • The present invention relates to novel compounds that are agonists of the glucagon-like peptide 1 (GLP-1) receptor and the glucose-dependent insulinotropic polypeptide (GIP) receptor with a protracted profile of action, suitable for oral administration to humans.
    • INCORPORATION-BY-REFERENCE OF THE SEQUENCE LISTING
  • The instant application contains a Sequence Listing which has been submitted in XML format via the USPTO patent electronic filing system and is hereby incorporated by reference in its entirety. Said XML file, created on Aug. 31, 2022, is named 200018US05.xml and is 98 kilobytes in size.
    • BACKGROUND
  • Glucagon-like peptide 1 (GLP-1) is a gut enteroendocrine cell-derived hormone and one of two prominent endogenous physiological incretins. GLP-1 improves glycemic control by stimulating glucose-dependent insulin secretion in response to nutrients (glucose), inhibits glucagon secretion from the pancreatic alpha-cells, slows gastric emptying, and induces body weight loss primary by decreasing food consumption. Glucose-dependent insulinotropic polypeptide (GIP), the other prominent incretin, improves glycemic control by stimulation of insulin secretion in response to nutrients (fat, glucose). Furthermore, GIP appears to improve plasma lipid profile and to stimulate calcium accumulation in bones. In contrast to GLP-1, the incretin effect of GIP is severely reduced in type 2 diabetes patients, though recent studies suggest that GIP efficiency can be regained in these patients after treatment to improve glucose control. Nonetheless, the role of GIP to regulate systemic metabolism beyond its direct effect at the endocrine pancreas remains controversial, particularly as it relates to GIP action to promote gain in fat mass in animal models. These results have fostered beliefs that GIPR antagonism can improve body weight. Thus, employment of compounds acting at GIP receptors, and specifically whether to agonize or antagonize, as a strategy to improve body weight remains a contentious subject of intense scientific investigation (Finan et al, TRENDS Mol Med, 2016, 22 (5): 359-376; Killion et al, Endo Rev, 2020, 41 (1): 1-21).
  • Protracted GIP analogs have been shown to lower body weight and improve glycemic control, though comparatively less potent than GLP-1 analogs to lower body weight in rodent models (Mroz et al, Mol Metab, 2019, 20: 51-62). Moreover, GIP analogs induce body weight loss by additive/synergistic action with GLP-1 analogs in dual administration (Finan et al, Sci Transl Med, 2013, 5 (209): 209ra151; Nørregaard et al, Diabetes Obes Metab, 2018, 20 (1): 60-68), and as such represent suitable candidates for amplification of GLP-1-based pharmacology. GIPR agonism can be recruited as a non-redundant partner to GLP-1R agonism as a single molecule co-agonist to amplify GLP-1 metabolic benefits, as has been shown in preclinical animal models, most notably body weight loss and glycemic control (Finan et al, Sci Transl Med, 2013, 5 (209): 209ra151; Coskun et al, Mol Metab, 2018, 18: 3-14). Two different peptides with high potency dual incretin receptor agonism have advanced to multi-dose clinical studies. The clinical results have demonstrated improvements in glycemic control and body weight that exceeds what is achieved with comparable dosing of benchmark GLP-1 specific agonists (Frias et al, Cell Metab, 2017, 26 (2): 343-352; Frias et al, Lancet, 2018, 392 (10160): 2180-2193), demonstrating the translational aspects and therapeutic benefits of co-targeting GLP-1 and GIP receptors.
  • Oral delivery of GLP-1 derivatives has been investigated clinically in the form of a once-daily tablet of semaglutide and the permeation enhancer sodium N-[8-(2-hydroxybenzoyl)amino]caprylate (SNAC) (Hedrington & Davis, Exp. Opin. Pharmacother. 2019, 20 (2): 133-141) to improve the very low typical exposure and bioavailability of GLP-1 derivatives following oral administration.
  • GLP-1/GIP co-agonists and their potential medical uses are described in several patent applications such as WO 2010/011439, WO 2013/164483, WO 2014/192284, WO 2015/067715, WO 2015/022420, WO 2015/086728, WO 2015/086729, WO 2016/111971, WO 2020/023386, U.S. Pat. No. 9,745,360, US 2014/162945, and US 2014/0357552. Patent applications disclosing oral delivery of GLP-1 derivatives are described in e.g. WO 2011/080103, WO 2012/080471, WO 2013/189988, and WO 2019/149880.
  • However, no co-agonistic products have so far obtained market approval.
    • SUMMARY
  • The present invention relates to single molecule co-agonists comprising a peptide and a substituent, which react with both the human GLP-1 and GIP receptors with high potency and are suitable for daily oral administration to humans. This is achieved by the combination of certain peptide sequence variants with substituents via a single site acylation with a diacid based fatty acid.
  • An aspect of the invention relates to a peptide having the amino acid sequence
  • (SEQ ID NO.: 36)
    YX2EGTX6TSDYSX12X13LEX16QAAX20X21FX23X24WLLX28GGP
    X32X33X34X35X36X37X38X39
      • with an optional amide modification of the C-terminus;
      • wherein
      • X2 is Aib or A
      • X6 is F or V
      • X12 is I or Y
      • X13 is Y, A, L or I
      • X16 is K or E
      • X20 is Q, R, E, H
      • X21 is A or E
      • X23 is I or V
      • X24 is E, Q or N
      • X28 is A or R
      • X32 is E, S or absent
      • X33 is S, K or absent
      • X34 is G or absent
      • X35 is A or absent
      • X36 is P or absent
      • X37 is P or absent
      • X38 is P or absent
      • X39 is S or absent.
  • In another aspect, the invention relates to a peptide having the amino acid sequence
  • (SEQ ID NO.: 36)
    YX2EGTX6TSDYSX12X13LEX16QAAX20X21FX23X24WLLX28GGP
    X32X33X34X35X36X37X38X39
      • with an optional amide modification of the C-terminus, wherein
      • X2 is Aib or A
      • X6 is F or V
      • X12 is I or Y
      • X13 is Y, A, L or I
      • X16 is K or E
      • X20 is Q, R, E, H
      • X21 is A or E
      • X23 is I or V
      • X24 is E, Q or N
      • X28 is A or R
      • X32 is E, S or absent
      • X33 is S, K or absent
      • X34 is G or absent
      • X35 is A or absent
      • X36 is P or absent
      • X37 is P or absent
      • X38 is P or absent
      • X39 is S or absent;
      • and a substituent attached to the peptide via Lysine (K) at position 16 or 33; or a pharmaceutically acceptable salt hereof.
  • A further aspect of the invention relates to a method for preparing the GLP-1/GIP co-agonists described herein.
  • In a further aspect the invention relates to a pharmaceutical composition comprising the GLP-1/GIP co-agonists compounds described herein.
  • A further aspect of the invention relates to medical use of the GLP-1/GIP co-agonists described herein.
  • In one aspect the invention relates to use of the GLP-1/GIP co-agonists described herein for prevention or treatment of diabetes, obesity, and/or liver diseases.
    • DESCRIPTION
  • In what follows, Greek letters may be represented by their symbol or the corresponding written name, for example: α=alpha; β=beta; ε=epsilon; γ=gamma; ω=omega; etc. Also, the Greek letter of μ may be represented by “u”, e.g. in μl=ul, or in μM=uM.
    • GLP-1/GIP Receptor Co-Agonist
  • The present invention relates to compounds that are GLP-1 receptor and the GIP receptor agonists, also referred to as GLP-1/GIP receptor co-agonists or simply co-agonists.
  • The term “compound” is used herein to refer to a molecular entity, and “compounds” may thus have different structural elements besides the minimum element defined for each compound or group of compounds. It follows that a compound may be a peptide or a derivative thereof, as long as the compound comprises the defined structural and/or functional elements.
  • The term “compound” is also meant to cover pharmaceutically relevant forms hereof, i.e. a compound as defined herein or a pharmaceutically acceptable salt, amide, or ester thereof.
  • The term “analogue” generally refers to a peptide, the sequence of which has one or more amino acid changes when compared to a reference amino acid sequence. An “analogue” may also include amino acid elongations in the N-terminal and/or C-terminal positions and/or truncations in the N-terminal and/or C-terminal positions.
  • In general, amino acid residues may be identified by their full name, their one-letter code, and/or their three-letter code. These three ways are fully equivalent.
  • Amino acids are molecules containing an amino group and a carboxylic acid group, and, optionally, one or more additional groups, often referred to as a side chain.
  • The term “amino acid” includes proteinogenic (or natural) amino acids (amongst those the 20 standard amino acids), as well as non-proteinogenic (or non-natural) amino acids. Proteinogenic amino acids are those which are naturally incorporated into proteins. The standard amino acids are those encoded by the genetic code. Non-proteinogenic amino acids are either not found in proteins, or not produced by standard cellular machinery (e.g., they may have been subject to post-translational modification). Non-limiting examples of non-proteinogenic amino acids are Aib (α-aminoisobutyric acid, or 2-aminoisobutyric acid), norleucine, norvaline as well as the D-isomers of the proteinogenic amino acids.
  • In what follows, each amino acid of the peptides for which the optical isomer is not stated is to be understood to mean the L-isomer (unless otherwise specified).
  • The GLP-1/GIP receptor co-agonists described herein comprise or consist of a peptide and a substituent as defined below. In some embodiments, the peptide is a synthetic peptide created to optimize the activity at the GLP-1 and GIP receptors. Compounds having a suitable receptor binding activity towards both the GLP-1 receptor and the GIP receptor have been identified as demonstrated in the examples herein.
  • The compounds further display an extended half-life gained by the substituent comprising a fatty acid group.
  • In some embodiments, the carboxy terminus of a peptide holds a —COOH group. In some embodiments, the compounds may optionally include an amide group (C(═O)—NH2) at the C-terminus, which is a naturally occurring modification substituting —OH with —NH2, such as seen with native Exendin-4.
  • Peptide
  • The GLP-1/GIP receptor co-agonists described herein comprise a peptide and a substituent as defined below, in which the substituent is attached to the peptide backbone via an amino acid residue.
  • In some embodiments, the amino acid sequence of the peptide is
  • (SEQ ID NO.: 47)
    YX2EGTX6TSDYSX12X13LEX16QAAX20X21FX23X24WLLX28G
    X30X31X32X33X34X35X36X37X38X39
      • with an optional amide modification of the C-terminus; wherein
      • X2 is Aib or A
      • X6 is F or V
      • X12 is I or Y
      • X13 is Y, A, L or I
      • X16 is K or E
      • X20 is Q, R, E, H
      • X21 is A or E
      • X23 is I or V
      • X24 is E, Q or N
      • X28 is A or R
      • X30 is G or absent
      • X31 is P or absent
      • X32 is E, S or absent
      • X33 is S, K or absent
      • X34 is G or absent
      • X35 is A or absent
      • X36 is P or absent
      • X37 is P or absent
      • X38 is P or absent
      • X39 is S or absent.
  • In some embodiments, the amino acid sequence of the peptide is
  • (SEQ ID NO.: 36)
    YX2EGTX6TSDYSX12X13LEX16QAAX20X21FX23X24WLLX28GGP
    X32X33X34X35X36X37X38X39
      • with an optional amide modification of the C-terminus;
      • wherein
      • X2 is Aib or A
      • X8 is F or V
      • X12 is I or Y
      • X13 is Y, A, L or I
      • X16 is K or E
      • X20 is Q, R, E, H
      • X21 is A or E
      • X23 is I or V
      • X24 is E, Q or N
      • X28 is A or R
      • X32 is E, S or absent
      • X33 is S, K or absent
      • X34 is G or absent
      • X35 is A or absent
      • X36 is P or absent
      • X37 is P or absent
      • X38 is P or absent
      • X39 is S or absent.
  • In one embodiment, X39 is absent. In one embodiment, X38 and X39 are absent. In one embodiment, X37, X38 and X39 are absent. In one embodiment, X36, X37, X38 and X39 are absent. In one embodiment, X35, X36, X37, X38 and X39 are absent. In one embodiment, X34, X35, X36, X37, X38 and X39 are absent. In one embodiment, X33, X34, X35, X36, X37, X38 and X39 are absent. In one embodiment, X32, X33, X34, X35, X36, X37, X38 and X39 are absent. In one embodiment, X31, X32, X33, X34, X35, X36, X37, X38 and X39 are absent. In one embodiment, X30, X31, X32, X33, X34, X35, X36, X37, X38 and X39 are absent. In further such embodiments, X32X33X34X35 is SSGA (SEQ ID NO.: 40). In further such embodiments, X32X33X34X35 is ESGA (SEQ ID NO.: 41). In further such embodiments, X32X33X34X35 is SKGA (SEQ ID NO.: 42). In a further embodiment thereof, the peptide has an amide modification of the C-terminus.
  • In one embodiment, the amino acid sequence of the peptide is
  • (SEQ ID NO.: 37)
    YX2EGTX6TSDYSX12X13LEX16QAAX20X21FX23X24WLLX28GGPS
    SGAPPPS
      • wherein
      • X2 is Aib or A
      • X6 is F or V
      • X12 is I or Y
      • X13 is Y, A, L or I
      • X16 is K or E
      • X20 is Q, R, E, H
      • X21 is A or E
      • X23 is I or V
      • X24 is E, Q or N
      • X28 is A or R.
  • In one embodiment, the amino acid sequence of the peptide is
  • (SEQ ID NO.: 38)
    YX2EGTX6TSDYSX12X13LEX16QAAX20X21FX23X24WLLX28GGPE
    SGAPPPS
      • wherein
      • X2 is Aib or A
      • X6 is F or V
      • X12 is I or Y
      • X13 is Y, A, L or I
      • X16 is K or E
      • X20 is Q, R, E, H
      • X21 is A or E
      • X23 is I or V
      • X24 is E, Q or N
      • X28 is A or R.
  • In one embodiment, the amino acid sequence of the peptide is
  • (SEQ ID NO.: 39)
    YX2EGTX6TSDYSX12X13LEX16QAAX20X21FX23X24WLLX28GGPS
    KGAPPPS
      • wherein
      • X2 is Aib or A
      • X6 is F or V
      • X12 is I or Y
      • X13 is Y, A, L or I
      • X16 is K or E
      • X20 is Q, R, E, H
      • X21 is A or E
      • X23 is I or V
      • X24 is E, Q or N
      • X28 is A or R.
  • In one embodiment, X2 is Aib. In one embodiment, X2 is A. In one embodiment, X6 is F. In one embodiment, X6 is V. In one embodiment, X12 is I. In one embodiment, X12 is Y. In one embodiment, X13 is Y. In one embodiment, X13 is A. In one embodiment, X13 is L. In one embodiment, X13 is I. In one embodiment, X16 is K. In one embodiment, X16 is E. In one embodiment, X20 is Q. In one embodiment, X20 is R. In one embodiment, X20 is E. In one embodiment, X20 is H. In one embodiment, X21 is A. In one embodiment, X21 is E. In one embodiment, X23 is I. In one embodiment, X23 is V. In one embodiment, X24 is E. In one embodiment, X24 is Q. In one embodiment, X24 is N. In one embodiment, X28 is A. In one embodiment, X28 is R. In one embodiment, X30 is G. In one embodiment, X31 is P.
  • In one embodiment, X13LEX16QAAX20X21FX23X24 is selected from the group consisting of: LLEKQAAREFIN (SEQ ID NO.: 43), LLEKQAAREFIE (SEQ ID NO.: 44), LLEKQAAQEFIE (SEQ ID NO.:45) and LLEEQAAREFIE (SEQ ID NO.: 46). In one embodiment, X13LEX16QAAX20X21FX23X24 is LLEKQAAREFIN (SEQ ID NO.: 43). In one embodiment, X13LEX16QAAX20X21FX23X24 is LLEKQAAREFIE (SEQ ID NO.: 44). In one embodiment, X13LEX16QAAX20X21FX23X24 is LLEKQAAQEFIE (SEQ ID NO.:45). In one embodiment, X13LEX16QAAX20X21FX23X24 is LLEEQAAREFIE (SEQ ID NO.: 46).
  • In a further embodiment, the amino acid sequence of the peptide is any one of SEQ ID NO.: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 33, 34 and 35.
  • In one embodiment, the amino acid sequence of the peptide is any one of SEQ ID NO.: 10, 22 or 25.
  • In one embodiment, the amino acid sequence of the peptide is SEQ ID NO.: 25.
  • In one embodiment, the amino acid sequence of the peptide is any one of SEQ ID NO.: 18, 20, 23, 24.
  • In one embodiment, the amino acid sequence of the peptide is SEQ ID NO.: 33, 34 or 35.
  • In further such embodiments, the peptide has an amide modification of the C-terminus.
    • Derivatives
  • In some embodiments, the GLP-1 and GIP receptor agonists comprise or consist of a substituent as defined below covalently linked to a peptide.
  • Such compounds may be referred to as derivatives of the peptide, as they are obtained by covalently linking a substituent to a peptide backbone.
  • An aspect of the invention relates to a compound comprising a peptide and a substituent; wherein the amino acid sequence of the peptide is:
  • (SEQ ID NO.: 47)
    YX2EGTX6TSDYSX12X13LEX16QAAX20X21FX23X24WLLX28GX30
    X31X32X33X34X35X36X37X38X39
  • with an optional amide modification of the C-terminus, wherein
  • X2 is Aib or A
  • X6 is F or V
  • X12 is I or Y
  • X13 is Y, A, L or I
  • X16 is K or E
  • X20 is Q, R, E, H
  • X21 is A or E
  • X23 is I or V
  • X24 is E, Q or N
  • X28 is A or R
  • X30 is G or absent
  • X31 is P or absent
  • X32 is E, S or absent
  • X33 is S, K or absent
  • X34 is G or absent
  • X35 is A or absent
  • X36 is P or absent
  • X37 is P or absent
  • X38 is P or absent
  • X39 is S or absent;
  • and wherein the substituent is attached to the peptide Lysine (K) at position 16 or 33;
  • or a pharmaceutically acceptable salt hereof.
  • An embodiment of the invention relates to a compound comprising a peptide and a substituent; wherein the amino acid sequence of the peptide is:
  • (SEQ ID NO.: 36)
    YX2EGTX6TSDYSX12X13LEX16QAAX20X21FX23X24WLLX28GGP
    X32X33X34X35X36X37X38X39
  • with an optional amide modification of the C-terminus, wherein
  • X2 is Aib or A
  • X6 is F or V
  • X12 is I or Y
  • X13 is Y, A, L or I
  • X16 is K or E
  • X20 is Q, R, E, H
  • X21 is A or E
  • X23 is I or V
  • X24 is E, Q or N
  • X28 is A or R
  • X32 is E, S or absent
  • X33 is S, K or absent
  • X34 is G or absent
  • X35 is A or absent
  • X36 is P or absent
  • X37 is P or absent
  • X38 is P or absent
  • X39 is S or absent;
  • and wherein the substituent is attached to the peptide via Lysine (K) at position 16 or 33;
  • or a pharmaceutically acceptable salt hereof.
  • In further embodiments, the peptide may be defined as described herein above.
    • Substituent
  • In one embodiment, the substituents described herein are attached to the peptide described herein via a lysine (K) residue in position 16 or 33.
  • In one embodiment, the substituent is attached to the peptide via the epsilon-amino group of a Lysine (K) when said Lysine is included at position 16 or 33.
  • In one embodiment, the substituent is a chemical structure covalently attached to the peptide that is capable of forming non-covalent complexes with plasma albumin, thereby promoting the circulation of the co-agonist with the blood stream, and also having the effect of protracting the time of action of the co-agonist, due to the fact that the complex of the co-agonist and albumin is only slowly removed by renal clearance.
  • In one embodiment, the substituent comprises a fatty acid group. In such an embodiment, the fatty acid group comprises a carbon chain which contains at least 8 consecutive —CH2— groups. In one embodiment, the fatty acid group comprises at least 10 consecutive —CH2— groups, such as least 12 consecutive —CH2— groups, at least 14 consecutive —CH2— groups, at least 16 consecutive —CH2— groups, or such as at least 18 consecutive —CH2— groups.
  • In one embodiment, the fatty acid group comprises 8-20 consecutive —CH2— groups. In one embodiment, the fatty acid group comprises 10-18 consecutive —CH2— groups. In one embodiment, the fatty acid group comprises 12-18 consecutive —CH2— groups. In one embodiment, the fatty acid group comprises 14-18 consecutive —CH2— groups.
  • In some embodiments, the substituent consists of several elements, such as a protractor element and one or more linker elements. In one embodiment, the term “protractor” is used to describe the fatty acid group which is the terminal part of the substituent responsible for extending half-life of the compound.
  • In one embodiment, the protractor (Prot) may be defined by:
  • Chem. 1: HOOC—(CH2)n—CO—* wherein n is an integer in the range of 8-20, which may also be referred to as a C(n+2) diacid or as
  • Figure US20230120597A1-20230420-C00001
  • wherein n is an integer in the range of 8-20.
  • In one embodiment, the substituent further comprises one or more linker elements. In some embodiments, the linker elements are linked to each other and the protractor by amide bonds and referred to as “Z” (see further below).
  • As further defined herein below the number of linker elements may be at most 3, referred to as—Z1-Z2-Z3- where Z1 is connected with the protractor (Prot) and the last Z element is connected with the peptide, in which case the substituent may be referred to as Prot-Z1-Z2-Z3-. The symbol*above thus indicates the attachment point to Z1, which when bound via an amide bond is a nitrogen. In an embodiment, where Z1 is a bond (see below), the symbol*indicates the attachment point to the nitrogen of the neighbouring Z element.
  • In one embodiment, the substituent is defined by: Prot-Z1-Z2-Z3- wherein Prot- is selected from Chem1, Chem 1 b, and wherein n is an integer in the range of 16-20.
  • In a particular embodiment, n is 14, 15, 16, 17, 18, 19 or 20 in Chem. 1 or Chem. 1b.
  • In a particular embodiment, n is 14, 15, 16, 17, or 18 in Chem. 1 or Chem. 1 b.
  • In a particular embodiment, n is 14, 16, or 18 in Chem. 1 or Chem. 1 b.
  • In a particular embodiment, n is 16, 17, 18, 19 or 20 in Chem. 1 or Chem. 1 b.
  • In a particular embodiment, n is 16, 18 or 20 in Chem. 1 or Chem. 1 b.
  • In a particular embodiment, n is 18 or 20 in Chem. 1 or Chem. 1 b.
  • In a particular embodiment, the protractor (Prot) is a C16 diacid or a C18 diacid.
  • In a particular embodiment, the protractor (Prot) is a C18 diacid or a C20 diacid.
  • In a particular embodiment, the protractor (Prot) is a C16, C18 diacid or a C20 diacid.
  • The term “bond” as used here means a covalent bond. When a linker element of Z1-Z3 is defined as a bond, it is equivalent to a situation wherein said linker element is absent. The indication herein below that any of Z1-Z3 is a bond may also be read as any of Z1-Z3 being absent, so that the previous Z element is covalently linked to the next Z element that is not “a bond” (or absent).
  • In some embodiments, the linker elements Z1-Z3 are individually selected from chemical moieties capable of forming amide bonds, including amino acid like moieties, such as Glu, γGlu (also termed gamma Glu or gGlu and defined by *—NH—CH—(COOH)—CH2—CH2—CO—*), ε-Lys (also termed epsilon Lys or eLys and defined by *—NH—(CH2)4—CH(NH2)—CO—*), Ser, Ala, Thr, Ado, Aeep and Aeeep and further moieties as described below.
  • In one embodiment, Z1 is selected from γGlu, Glu, or a bond.
  • In one embodiment, Z1 is γGlu.
  • In one embodiment, Z2 and Z3, are selected, independently of each other, from Glu, ε-Lys, γGlu, Gly, Ser, Ala, Thr, Ado, Aeep, Aeeep and a bond.
  • Glu, Gly, Ser, Ala, Thr are amino acid residues well known in the art.
  • ε-Lys is defined by Chem. 2: *—NH—(CH2)4—CH(NH2)—CO—* which may also be described by
  • Figure US20230120597A1-20230420-C00002
  • γGlu is defined by Chem. 3: *—NH—CH(COOH)—(CH2)2—CO—* which may also be described by
  • Figure US20230120597A1-20230420-C00003
  • Ado is defined by Chem. 4: *—NH—(CH2)2—O—(CH2)2—O—CH2—CO—* may also be referred to as 8-amino-3,6-dioxaoctanoic acid and which may also be described by
  • Figure US20230120597A1-20230420-C00004
  • Aeep is defined by Chem. 5: *NH—CH2CH2OCH2CH2OCH2CH2CO*, which may also be described by
  • Figure US20230120597A1-20230420-C00005
  • Aeeep is defined of Chem. 6: *NH—CH2CH2OCH2CH2OCH2CH2OCH2CH2CO*, which may also be described by
  • Figure US20230120597A1-20230420-C00006
  • In one embodiment, Z2 and Z3 are selected, independently of each other, from Glu, ε-Lys, γGlu, Gly, Ala, Ado, Aeep, Aeeep and a bond.
  • In one embodiment, Z2 and Z3 are selected, independently of each other, from Glu, ε-Lys, γGlu, Gly, Ala, Ado and a bond.
  • In one embodiment, Z2 and Z3 are selected, independently of each other, from Glu, ε-Lys, γGlu, Gly, Ado and a bond.
  • In one embodiment, Z2 and Z3 are selected, independently of each other, from ε-Lys, γGlu, Gly, Ado and a bond.
  • In one embodiment, Z2 and Z3 are selected, independently of each other, from ε-Lys, γGlu, Ado and a bond.
  • In one embodiment, Z2 and Z3 are ε-Lys or Ado.
  • In one embodiment, Z2 and Z3 are Ado.
  • In one embodiment, Z2 and Z3 are ε-Lys.
  • In one embodiment, the substituent is selected from substituents A, B, C, D, and E defined as below.
  • In one embodiment, the substituent is selected from substituents A, B and C defined as follows:
  • Substituent # Prot Z1 Z2 Z3
    A C18 diacid γGlu Ado Ado
    B C18 diacid γGlu εLys εLys
    C C20 diacid γGlu εLys εLys
    D C16 diacid γGlu Ado Ado
    E C16 diacid γGlu εLys εLys
  • In some embodiments, the substituent is covalently attached to a lysine residue of the co-agonist by acylation, i.e. via an amide bond formed between a carboxylic acid group of the substituent and the epsilon-amino group of the lysine residue.
  • In one embodiment, the substituent is covalently attached to a lysine residue in position 16 of the peptide backbone by acylation, i.e., via an amide bond formed between a carboxylic acid group of the substituent and the epsilon amino group of the lysine residue.
  • In one embodiment, the substituent is covalently attached to a lysine residue in position 33 of the peptide backbone by acylation, i.e., via an amide bond formed between a carboxylic acid group of the substituent and the epsilon amino group of the lysine residue.
  • The co-agonists may exist in different stereoisomeric forms having the same molecular formula and sequence of bonded atoms but differing only in the three-dimensional orientation of their atoms in space. The stereoisomerism of the exemplified co-agonists is indicated in the experimental section, in the names as well as the structures, using standard nomenclature. Unless otherwise stated the invention relates to all stereoisomeric forms of the embodied derivative.
    • Functional Receptor Activation Activity
  • The functional activity of the GLP-1/GIP receptor agonists as described herein can be tested in vitro as described herein in Example 2.
  • The term half maximal effective concentration (EO50) generally refers to the concentration which induces a response halfway between the baseline and maximum, by reference to the dose response curve. EC50 is used as a measure of the potency of a compound and represents the concentration where 50% of its maximal effect is observed.
  • The in vitro potency of compounds may thus be determined as described herein and the EC50 determined. The lower the EC50 value, the better the potency.
  • In order to characterize such compounds, it may further be relevant to consider the in vitro potencies relative to the native hormones of each receptor.
  • The in vitro potency may, e.g., be determined in a medium containing membranes expressing the appropriate GLP-1 and/or GIP receptor, and/or in an assay with whole cells expressing the appropriate GLP-1 and/or GIP receptor.
  • For example, the functional response of the human GLP-1 and/or GIP receptor may be measured in a reporter gene assay, e.g. in a stably transfected BHK cell line that expresses the human GLP-1 and/or GIP receptor and contains the DNA for the cAMP response element (CRE) coupled to a promoter and the gene for firefly luciferase (CRE luciferase). When cAMP is produced as a result of activation of the GLP-1 and/or GIP receptor, this in turn results in luciferase being expressed. Luciferase may be determined by adding luciferin, which by the enzyme is converted to oxyluciferin and produces bioluminescence, which is measured as a reporter of the in vitro potency. One example of such an assay is described in Example 2 as described herein. Since the compounds may include a substituent designed to bind albumin, it is also important to note that the receptor activity may be affected by the presence or absence of human serum albumin (HSA) in the assay medium. A decrease in potency of the compound in the presence of HSA, indicated by an increase in EC50 compared to the EC50 in the absence of HSA, indicates interaction of the compounds with HSA and predicts a protracted time of action in vivo.
  • In one embodiment, the compounds have potent in vitro effects to activate the human GLP-1 and GIP receptors.
  • In one embodiment, the compounds are capable of activating the human GLP-1 and GIP receptors in vitro with an EC50 of less than 20 pM in CRE luciferase reporter assays as described in Example 2 herein, when performed without HSA.
  • In one embodiment, the compounds have an in vitro potency at the human GLP-1 and GIP receptors determined using the method of Example 2 corresponding to an EC50 at or below 100 pM, more preferably below 50 pM, or most preferably below 20 pM.
  • In one embodiment, the EC50 in human GLP-1 and GIP receptors assays are both 1-25 pM, such as 1-20 pM, such as 1-15 pM or such as 1-10 pM.
    • Pharmacokinetics Properties
  • The pharmacokinetic properties of the co-agonistic compounds may further be determined in vivo via pharmacokinetic (PK) studies. Animal models such as the mouse, rat, monkey, dog, or pig may be used to perform this characterization.
  • In such studies, animals are typically administered with a single dose of the drug, either intravenously, subcutaneously (s.c.), or orally (p.o.) in a relevant formulation. Blood samples are drawn at predefined time points after dosing, and samples are analysed for concentration of drug with a relevant quantitative assay. Based on these measurements, time-plasma concentration profiles for the compound of study are plotted and a so-called non-compartmental pharmacokinetic analysis of the data is performed. An important parameter is the terminal half-life as a long half-life indicates that less frequent administration of a compound may be possible. The terminal half-life (t½) in vivo may be measured using a suitable model, such as after i.v. administration in minipigs described in Example 3; or after p.o administration in dogs described in Example 4.
  • In one embodiment, the terminal half-life is half-life (t½) in vivo in minipigs after i.v. administration, e.g. as described in Example 3 herein.
  • In one embodiment, the terminal half-life in minipigs is at least 24 hours, such as at least 30 hours, or such as at least 40 hours.
  • In one embodiment, the terminal half-life is half-life (t½) in vivo in dogs after p.o. administration, e.g. as described in Example 4 herein.
  • In one embodiment, the terminal half-life in dogs is at least 24 hours, such as at least 40 hours, or such as at least 50 hours.
    • Pharmaceutically Acceptable Salts
  • In some embodiments, the co-agonists as described herein are in the form of a pharmaceutically acceptable salt. Salts are e.g. formed by a chemical reaction between a base and an acid, e.g.: 2NH3+H2SO4→(NH4)2SO4. The salt may be a basic salt, an acid salt, or it may be neither (i.e. a neutral salt). Basic salts produce hydroxide ions and acid salts hydronium ions in water. The salts of the co-agonists may be formed with added cations or anions between anionic or cationic groups, respectively. These groups may be situated in the peptide and/or in the substituent of the derivatives. Non-limiting examples of anionic groups include any free carboxylic acid groups in the substituent, if any, as well as in the peptide. The peptide may include a free carboxylic acid group at the C-terminus, if present, as well as any free carboxylic acid group of internal acidic amino acid residues such as Asp and Glu.
  • Non-limiting examples of cationic groups include any free amino groups in the substituent, if any, as well as in the peptide. The peptide may include a free amino group at the N-terminus, if present, as well as any free imidazole or amino group of internal basic amino acid residues such as His, Arg, and Lys.
  • In a particular embodiment, the peptide or derivative is in the form of a pharmaceutically acceptable salt.
    • Production Processes
  • The co-agonists may for instance be produced by classical peptide synthesis, e.g. solid phase peptide synthesis using t-Boc or Fmoc chemistry or other well established techniques, see e.g. Greene and Wuts, “Protective Groups in Organic Synthesis”, John Wiley & Sons, 1999; Florencio Zaragoza Dörwald, “Organic Synthesis on Solid Phase”, Wiley-VCH Verlag GmbH, 2000; and “Fmoc Solid Phase Peptide Synthesis”, Edited by W. C. Chan and P. D. White, Oxford University Press, 2000.
  • Alternatively, the compounds may be produced by recombinant methods, e.g. by culturing a host cell containing a DNA sequence encoding the peptide sequence and capable of expressing the peptide, in a suitable nutrient medium under conditions permitting the expression of the peptide. Non-limiting examples of host cells suitable for expression of these peptides are: Escherichia coli, Saccharomyces cerevisiae, as well as mammalian BHK or CHO cell lines.
  • The co-agonists that include non-natural amino acids and/or covalently attached substituents may be produced as described in the experimental part.
  • Specific examples of methods of preparing a number of co-agonists are included in the experimental part.
  • A further aspect of the invention relates to a method for preparing the peptides described herein.
  • A further aspect of the invention relates to a method for preparing the GLP-1/GIP co-agonists described herein.
  • In one embodiment, the method for preparing a compound as described herein comprises a step of solid phase peptide synthesis. The substituent may be built sequentially as part of the solid phase peptide synthesis or produced separately and attached via the lysine residue after peptide synthesis.
  • In one embodiment, the compounds are produced by a two-step process whereby two peptide fragments are ligated after attachment of the substituent to one of the peptide fragments.
    • Pharmaceutical Compositions
  • In a further aspect the invention relates to a pharmaceutical composition comprising a GLP-1/GIP receptor co-agonist as described herein. Compositions comprising the compound or a pharmaceutically acceptable salt hereof, and optionally one or more a pharmaceutically acceptable excipients may be prepared as is known in the art.
  • The term “excipient” broadly refers to any component other than the active therapeutic ingredient(s). The excipient may be an inert substance, an inactive substance, and/or a not medicinally active substance. The excipient may serve various purposes, e.g. as a carrier, vehicle, filler, binder, lubricant, glidant, disintegrant, flow control agent, crystallization inhibitor, solubilizer, stabilizer, coloring agent, flavoring agent, surfactant, emulsifier or combinations thereof and/or to improve administration, and/or to improve absorption of the active substance. The amount of each excipient used may vary within ranges conventional in the art. Techniques and excipients which may be used to formulate oral dosage forms are described in Handbook of Pharmaceutical Excipients (e.g. 8th edition, Sheskey et al., Eds., American Pharmaceuticals Association and Pharmaceutical Press, publications department of the Royal Pharmaceutical Society of Great Britain (2017), and any later editions); and Remington: The Science and Practice of Pharmacy (e.g. 22nd edition, Remington and Allen, Eds., Pharmaceutical Press (2013), and any later editions).
  • In one embodiment, the pharmaceutical composition may be a solid formulation, e.g. a freeze-dried or spray-dried composition, which may be used as is, or whereto the physician or the patient adds solvents, and/or diluents prior to use. In a further embodiment, the pharmaceutical composition may be a solid formulation consisting of the active ingredient, a salt of N-[8-(2-hydroxybenzoyl)amino]caprylate, and one or more further excipients as is known in the art, e.g. using any one or more of the formulations described in WO 2012/080471, WO 2013/189988, or WO 2019/149880.
  • Alternatively, the pharmaceutical composition is a liquid formulation, such as an aqueous formulation. Liquid compositions, suitable for injection, can be prepared using conventional techniques of the pharmaceutical industry which involve dissolving and mixing the ingredients as appropriate to give the desired end product. Thus, according to one procedure, a GLP-1/GIP co-agonist as described herein is dissolved in a suitable buffer at a suitable pH. The composition may be sterilized, for example, by sterile filtration.
    • Pharmaceutical Indications
  • A further aspect of the invention relates to the use of GLP-1/GIP receptor co-agonist compounds as described herein as a medicament.
  • In one embodiment, the compounds described herein are for use in the following medical treatments:
      • (i) prevention and/or treatment of all forms of diabetes, such as hyperglycemia, type 2 diabetes, impaired glucose tolerance, type 1 diabetes, non-insulin dependent diabetes, MODY (maturity onset diabetes of the young), gestational diabetes, and/or for reduction of HbA1C;
      • (ii) delaying or preventing diabetic disease progression, such as progression in type 2 diabetes, delaying the progression of impaired glucose tolerance (IGT) to insulin requiring type 2 diabetes, delaying or preventing insulin resistance, and/or delaying the progression of non-insulin requiring type 2 diabetes to insulin requiring type 2 diabetes;
      • (iii) prevention and/or treatment of eating disorders, such as obesity, e.g. by decreasing food intake, reducing body weight, suppressing appetite, inducing satiety; treating or preventing binge eating disorder, bulimia nervosa, and/or obesity induced by administration of an antipsychotic or a steroid; reduction of gastric motility; delaying gastric emptying; increasing physical mobility; and/or prevention and/or treatment of comorbidities to obesity, such as osteoarthritis and/or urine incontinence;
      • (iv) weight maintenance after successful weight loss (either drug induced or by diet and exercise)—i.e. prevention of weight gain after successful weight loss.
      • (v) prevention and/or treatment of liver disorders, such as hepatic steatosis, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), liver inflammation or fatty liver.
  • In one embodiment, the compounds are for use in a method for prevention and/or treatment of diabetes and/or obesity.
  • In one embodiment, the compounds are for use in a method for treatment of diabetes and/or obesity.
  • In one embodiment, the compounds are for use in a method for treatment or prevention of type 2 diabetes.
  • In one embodiment, the compounds are for use in a method for treatment of type 2 diabetes.
  • In one embodiment, the compounds are for use in a method for treatment or prevention of obesity.
  • In one embodiment, the compounds are for use in a method for treatment of obesity.
  • In one embodiment, the compounds are for use in a method for weight management. In one embodiment, the compounds are for use in a method for reduction of appetite. In one embodiment, the compounds are for use in a method for reduction of food intake.
    • EMBODIMENTS
      • 1. A compound comprising a peptide and a substituent; wherein the amino acid sequence of the peptide is
  • (SEQ ID NO.: 47)
    YX2EGTX6TSDYSX12X13LEX16QAAX20X21FX23X24WLLX28GX30X31X32
    X33X34X35X33X37X38X39 
        • with an optional amide modification of the C-terminus, wherein
        • X2 is Aib or A
        • X6 is F or V
        • X12 is I or Y
        • X13 is Y, A, L or I
        • X16 is K or E
        • X20 is Q, R, E, H
        • X21 is A or E
        • X23 is I or V
        • X24 is E, Q or N
        • X28 is A or R
        • X30 is G or absent
        • X31 is P or absent
        • X32 is E, S or absent
        • X33 is S, K or absent
        • X34 is G or absent
        • X35 is A or absent
        • X36 is P or absent
        • X37 is P or absent
        • X38 is P or absent
        • X39 is S or absent;
        • and wherein the substituent is attached to the peptide via Lysine (K) at position 16 or 33;
        • or a pharmaceutically acceptable salt hereof.
      • 2. The compound according to embodiment 1, comprising a peptide and a substituent; wherein the amino acid sequence of the peptide is
  • (SEQ ID NO.: 36)
    YX2EGTX6TSDYSX12X13LEX16QAAX20X21FX23X24WLLX28GGPX32X33
    X34X35X36X37X38X39 
        • with an optional amide modification of the C-terminus, wherein
        • X2 is Aib or A
        • X6 is F or V
        • X12 is I or Y
        • X13 is Y, A, L or I
        • X16 is K or E
        • X20 is Q, R, E, H
        • X21 is A or E
        • X23 is I or V
        • X24 is E, Q or N
        • X28 is A or R
        • X32 is E, S or absent
        • X33 is S, K or absent
        • X34 is G or absent
        • X35 is A or absent
        • X36 is P or absent
        • X37 is P or absent
        • X38 is P or absent
        • X39 is S or absent;
        • and wherein the substituent is attached to the peptide via Lysine (K) at position 16 or 33;
        • or a pharmaceutically acceptable salt hereof.
      • 3. The compound according to embodiment 1, wherein X36, X37, X38 and X39 are absent.
      • 4. The compound according to embodiment 1, wherein X34, X35, X36, X37, X38 and X39 are absent.
      • 5. The compound according to embodiment 1, wherein X32, X33, X34, X35, X36, X37, X38 and X39 are absent.
      • 6. The compound according to embodiment 1, wherein X30, X31, X32, X33, X34, X35, X36, X37, X38 and X39 are absent.
      • 7. The compound according to any one of embodiments 1-6, wherein the peptide has the amide modification of the C-terminus.
      • 8. The compound according to any of the previous embodiments 1, 2 or 7, wherein X32X33X34X35 is selected from the group consisting of SSGA (SEQ ID NO.: 40), ESGA (SEQ ID NO.: 41) and SKGA (SEQ ID NO.: 42).
      • 9. The compound according to any of the previous embodiments 1, 2 or 7, wherein
  • (SEQ ID NO.: 40)
    X32X33X34X35 SSGA.
      • 10. The compound according to any of the previous embodiments 1, 2 or 7, wherein
  • (SEQ ID NO.: 41)
    X32X33X34X35 is ESGA 
      • 11. The compound according to any of the previous embodiments 1, 2 or 7, wherein
  • (SEQ ID NO.: 42)
    X32X33X34X35 is SKGA.
      • 12. The compound according to embodiment 1, wherein the amino acid sequence of the peptide is
  • (SEQ ID NO.: 37)
    YX2EGTX6TSDYSX12X13LEX16QAAX20X21FX23X24WLLX28GGPSSGA
    PPPS
      • wherein
        • X2 is Aib or A
        • X6 is F or V
        • X12 is I or Y
        • X13 is Y, A, L or I
        • X16 is K or E
        • X20 is Q, R, E, H
        • X21 is A or E
        • X23 is I or V
        • X24 is E, Q or N
        • X28 is A or R.
      • 13. The compound according to embodiment 1, wherein the amino acid sequence of the peptide is
  • (SEQ ID NO.: 38)
    YX2EGTX6TSDYSX12X13LEX16QAAX20X21FX23X24WLLX28GGPESGAPPPS
      • wherein
        • X2 is Aib or A
        • X6 is F or V
        • X12 is I or Y
        • X13 is Y, A, L or I
        • X16 is K or E
        • X20 is Q, R, E, H
        • X21 is A or E
        • X23 is I or V
        • X24 is E, Q or N
        • X28 is A or R.
      • 14. The compound according to embodiment 1, wherein the amino acid sequence of the peptide is
  • (SEQ ID NO 39)
    YX2EGTX6TSDYSX12X13LEX16QAAX20X21FX23X24WLLX28GGPSKGAPPPS
        • wherein
        • X2 is Aib or A
        • X6 is F or V
        • X12 is I or Y
        • X13 is Y, A, L or I
        • X16 is K or E
        • X20 is Q, R, E, H
        • X21 is A or E
        • X23 is I or V
        • X24 is E, Q or N
        • X28 is A or R.
      • 15. The compound according to any of the previous embodiments, wherein X13LEX16QAAX20X21FX23X24 is selected from the group consisting of:
  • (SEQ ID NO.: 43)
    LLEKQAAREFIN,
    (SEQ ID NO.: 44)
    LLEKQAAREFIE,  
    (SEQ ID NO.: 45)
    LLEKQAAQEFIE
    and 
    (SEQ ID NO.: 46)
    LLEEQAAREFIE. 
      • 16. The compound according to embodiment 1, wherein the amino acid sequence of the peptide is any one of SEQ ID NO.: 1-27 or 33-35.
      • 17. The compound according to embodiment 16, wherein the peptide has the amide modification of the C-terminus.
      • 18. The compound according to any of the previous embodiments, wherein the compound activates the human GLP-1 and GIP receptors in vitro with an EC50 of less than 20 pM when measured without HSA in CRE luciferase reporter assays as described in Example 2.
      • 19. The compound according to any of the previous embodiments, wherein the compound has a half-life in minipigs of at least 35 hours.
      • 20. The compound according to any of the previous embodiments, wherein the substituent is attached via 16Lys.
      • 21. The compound according to any of the previous embodiments, wherein the substituent is attached via 33Lys.
      • 22. The compound according to any of the previous embodiments, wherein the substituent comprises at least one protractor.
      • 23. The compound according to embodiment 22, wherein the protractor is a fatty acid group.
      • 24. The compound according to embodiment 23, wherein the protractor is a diacid defined by Chem. 1: HOOC—(CH2)n—CO— wherein n is an integer in the range of 8-20, such as n=14, 16 or 18.
      • 25. The compound according to embodiment 23, wherein the protractor is a diacid defined by Chem. 1: HOOC—(CH2)n—CO— wherein n is an integer in the range of 8-20, such as n=16 or 18.
      • 26. The compound according to any of the previous embodiments, wherein the substituent comprises at least one linker element.
      • 27. The compound according to embodiment 26, wherein the substituent comprises at most three linker elements.
      • 28. The compound according to embodiment 27, wherein the substituent comprises at most three linker elements referred to as—Z1-Z2-Z3-, where —Z1- is connected with the protractor and —Z3- is connected to the peptide.
      • 29. The compound according to any of the previous embodiments, wherein the substituent is:
      • Prot-Z1-Z2-Z3-
        • wherein
      • Prot is a C16-C20 diacid
      • Z1 is γGlu or a bond
      • Z2 is εLys, γGlu or Ado and
      • Z3 is εLys or Ado.
      • 30. The compound according to embodiment 29, wherein —Z1- is -γGlu-.
      • 31. The compound according to embodiments 29 or 30, wherein —Z2-Z3- and is -Ado-Ado-.
      • 32. The compound according to embodiments 29, 30 or 31, wherein —Z2-Z3- and is -εLys-εLys-.
  • 33. The compound according to any of the embodiments 1-17, wherein the substituent is selected from the group consisting of:
  • Figure US20230120597A1-20230420-C00007
      • 34. The compound according to any of the embodiments 1-17, wherein the substituent is selected from the group consisting of:
  • Figure US20230120597A1-20230420-C00008
      • 35. The compound according to any of the previous embodiments 1-17, wherein the substituent is attached to the peptide via the epsilon-amino group of a Lysine (K).
      • 36. The compound according to embodiment 1, wherein the compound is selected from the group consisting of:
  •
    Compound No. 1
    SEQ ID NO: 1
    Substituent: C
    Figure US20230120597A1-20230420-C00009
    Compound No. 2
    SEQ ID NO: 2
    Substituent: C
    Figure US20230120597A1-20230420-C00010
    Compound No. 3
    SEQ ID NO: 2
    Substituent: B
    Figure US20230120597A1-20230420-C00011
    Compound No. 4
    SEQ ID NO: 3
    Substituent: B
    Figure US20230120597A1-20230420-C00012
    Compound No. 5
    SEQ ID NO: 3
    Substituent: B
    Figure US20230120597A1-20230420-C00013
    Compound No. 6
    SEQ ID NO: 4
    Substituent: B
    Figure US20230120597A1-20230420-C00014
    Compound No. 7
    SEQ ID NO: 4
    Substituent: A
    Figure US20230120597A1-20230420-C00015
    Compound No. 8
    SEQ ID NO: 5
    Substituent: B
    Figure US20230120597A1-20230420-C00016
    Compound No. 9
    SEQ ID NO: 6
    Substituent: B
    Figure US20230120597A1-20230420-C00017
    Compound No. 10
    SEQ ID NO: 6
    Substituent: A
    Figure US20230120597A1-20230420-C00018
    Compound No. 11
    SEQ ID NO: 5
    Substituent: B
    Figure US20230120597A1-20230420-C00019
    Compound No. 12
    SEQ ID NO: 7
    Substituent: B
    Figure US20230120597A1-20230420-C00020
    Compound No. 13
    SEQ ID NO: 8
    Substituent: B
    Figure US20230120597A1-20230420-C00021
    Compound No. 14
    SEQ ID NO: 9
    Substituent: B
    Figure US20230120597A1-20230420-C00022
    Compound No. 15
    SEQ ID NO: 10
    Substituent: B
    Figure US20230120597A1-20230420-C00023
    Compound No. 16
    SEQ ID NO: 5
    Substituent: C
    Figure US20230120597A1-20230420-C00024
    Compound No. 17
    SEQ ID NO: 11
    Substituent: B
    Figure US20230120597A1-20230420-C00025
    Compound No. 18
    SEQ ID NO: 12
    Substituent: B
    Figure US20230120597A1-20230420-C00026
    Compound No. 19
    SEQ ID NO: 13
    Substituent: B
    Figure US20230120597A1-20230420-C00027
    Compound No. 20
    SEQ ID NO: 14
    Substituent: B
    Figure US20230120597A1-20230420-C00028
    Compound No. 21
    SEQ ID NO: 15
    Substituent: B
    Figure US20230120597A1-20230420-C00029
    Compound No. 22
    SEQ ID NO: 16
    Substituent: B
    Figure US20230120597A1-20230420-C00030
    Compound No. 23
    SEQ ID NO: 17
    Substituent: B
    Figure US20230120597A1-20230420-C00031
    Compound No. 24
    SEQ ID NO: 18
    Substituent: B
    Figure US20230120597A1-20230420-C00032
    Compound No. 25
    SEQ ID NO: 19
    Substituent: B
    Figure US20230120597A1-20230420-C00033
    Compound No. 26
    SEQ ID NO: 20
    Substituent: B
    Figure US20230120597A1-20230420-C00034
    Compound No. 27
    SEQ ID NO: 21
    Substituent: B
    Figure US20230120597A1-20230420-C00035
    Compound No. 28
    SEQ ID NO: 22
    Substituent: B
    Figure US20230120597A1-20230420-C00036
    Compound No. 29
    SEQ ID NO: 23
    Substituent: B
    Figure US20230120597A1-20230420-C00037
    Compound No. 30
    SEQ ID NO: 24
    Substituent: B
    Figure US20230120597A1-20230420-C00038
    Compound No. 31
    SEQ ID NO: 25
    Substituent: B
    Figure US20230120597A1-20230420-C00039
    Compound No. 32
    SEQ ID NO: 25
    Substituent: A
    Figure US20230120597A1-20230420-C00040
    Compound No. 33
    SEQ ID NO: 26
    Substituent: B
    Figure US20230120597A1-20230420-C00041
    Compound No. 34
    SEQ ID NO: 27
    Substituent: B
    Figure US20230120597A1-20230420-C00042
    Compound No. 35
    SEQ ID NO: 10
    Substituent: A
    Figure US20230120597A1-20230420-C00043
    Compound No. 36
    SEQ ID NO: 27
    Substituent: A
    Figure US20230120597A1-20230420-C00044
    Compound No. 42
    SEQ ID NO: 33
    Substituent: B
    Figure US20230120597A1-20230420-C00045
    Compound No. 43
    SEQ ID NO: 34
    Substituent: B
    Figure US20230120597A1-20230420-C00046
    Compound No. 44
    SEQ ID NO: 35
    Substituent: B
    Figure US20230120597A1-20230420-C00047
    Compound No. 45
    SEQ ID NO: 34
    Substituent: A
    Figure US20230120597A1-20230420-C00048
    Compound No. 46
    SEQ ID NO: 34
    Substituent: E
    Figure US20230120597A1-20230420-C00049
    Compound No. 47
    SEQ ID NO: 34
    Substituent: D
    Figure US20230120597A1-20230420-C00050
      • 37. The compound according to embodiment 1, wherein the compound is selected from the group consisting of:
  •
    Compound No. 15
    SEQ ID NO: 10
    Substituent: B
    Figure US20230120597A1-20230420-C00051
    Compound No. 31
    SEQ ID NO: 25
    Substituent: B
    Figure US20230120597A1-20230420-C00052
    Compound No. 32
    SEQ ID NO: 25
    Substituent: A
    Figure US20230120597A1-20230420-C00053
    Compound No. 28
    SEQ ID NO: 22
    Substituent: B
    Figure US20230120597A1-20230420-C00054
    Compound No. 29
    SEQ ID NO: 23
    Substituent: B
    Figure US20230120597A1-20230420-C00055
    Compound No. 43
    SEQ ID NO: 34
    Substituent: B
    Figure US20230120597A1-20230420-C00056
    Compound No. 46
    SEQ ID NO: 34
    Substituent: E
    Figure US20230120597A1-20230420-C00057
    Compound No. 47
    SEQ ID NO: 34
    Substituent: D
    Figure US20230120597A1-20230420-C00058
      • 38. The compound according to embodiment 1, wherein the compound is selected from the group consisting of:
  •
    Compound No. 15
    SEQ ID NO: 10
    Substituent: B
    Figure US20230120597A1-20230420-C00059
    Compound No. 31
    SEQ ID NO: 25
    Substituent: B
    Figure US20230120597A1-20230420-C00060
    Compound No. 32
    SEQ ID NO: 25
    Substituent: A
    Figure US20230120597A1-20230420-C00061
    Compound No. 28
    SEQ ID NO: 22
    Substituent: B
    Figure US20230120597A1-20230420-C00062
    Compound No. 29
    SEQ ID NO: 23
    Substituent: B
    Figure US20230120597A1-20230420-C00063
    Compound No. 46
    SEQ ID NO: 34
    Substituent: E
    Figure US20230120597A1-20230420-C00064
    Compound No. 47
    SEQ ID NO: 34
    Substituent: D
    Figure US20230120597A1-20230420-C00065
      • 39. The compound according to embodiment 1, wherein the compound is:
  •
    SEQ ID NO: 34
    Substituent: B
    Figure US20230120597A1-20230420-C00066
         		Compound No. 43
    SEQ ID NO: 34
    Substituent: E
    Figure US20230120597A1-20230420-C00067
         		Compound No. 46
    SEQ ID NO: 34
    Substituent: D
    Figure US20230120597A1-20230420-C00068
         		Compound No. 47
      • 40. The compound according to embodiment 1, wherein the compound is:
  •
    SEQ ID NO: 25
    Substituent: B
    Figure US20230120597A1-20230420-C00069
         		Compound No. 31
      • 41. A compound according to any of the previous embodiments for use as a medicament.
      • 42. A pharmaceutical composition comprising a compound according to any of the previous embodiments 1-40.
      • 43. The composition according to embodiment 42, wherein said composition is an aqueous liquid.
      • 44. The composition according to embodiment 42, wherein said composition is a solid composition.
      • 45. A pharmaceutical composition according to any of the embodiments 42-44 for prevention and/or treatment of diabetes and/or obesity.
      • 46. A pharmaceutical composition according to any of the embodiments 42-44 for prevention and/or treatment of liver disorders, such as hepatic steatosis, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH) liver inflammation and/or fatty liver.
      • 47. A method for prevention and/or treatment of diabetes and/or obesity comprising administering to a patient a pharmaceutically active amount of the compound according to any one of embodiments 1-40.
      • 48. A method for prevention and/or treatment of liver disorders, such as hepatic steatosis, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH) liver inflammation and/or fatty liver comprising administering to a patient a pharmaceutically active amount of the compound according to any one of embodiments 1-40.
      • 49. A peptide, wherein the amino acid sequence of the peptide is
  • (SEQ ID NO.: 47)
    YX2EGTX6TSDYSX12X13LEX16QAAX20X21FX23X24WLLX28GX30X31X32X33
    X34X35X36X37X38X39 
        • with an optional amide modification of the C-terminus,
        • wherein
          • X2 is Aib or A
          • X6 is F or V
          • X12 is I or Y
          • X13 is Y, A, L or I
          • X16 is K or E
          • X20 is Q, R, E, H
          • X21 is A or E
          • X23 is I or V
          • X24 is E, Q or N
          • X28 is A or R
          • X30 is G or absent
          • X31 is P or absent
          • X32 is E, S or absent
          • X33 is S, K or absent
          • X34 is G or absent
          • X35 is A or absent
          • X36 is P or absent
          • X37 is P or absent
          • X38 is P or absent
          • X39 is S or absent.
      • 50. A peptide, wherein the amino acid sequence of the peptide is
  • (SEQ ID NO.: 36)
    YX2EGTX6TSDYSX12X13LEX16QAAX20X21FX23X24WLLX28GGPX32X33X34
    X35X36X37X38X39 
        • with an optional amide modification of the C-terminus,
        • wherein
          • X2 is Aib or A
          • X6 is F or V
          • X12 is I or Y
          • X13 is Y, A, L or I
          • X16 is K or E
          • X20 is Q, R, E, H
          • X21 is A or E
          • X23 is I or V
          • X24 is E, Q or N
          • X28 is A or R
          • X32 is E, S or absent
          • X33 is S, K or absent
          • X34 is G or absent
          • X35 is A or absent
          • X36 is P or absent
          • X37 is P or absent
          • X38 is P or absent
          • X39 is S or absent.
      • 51. The peptide according to embodiment 49, wherein X36, X37, X38 and X39 are absent.
      • 52. The peptide according to embodiment 49, wherein X34, X35, X36, X37, X38 and X39 are absent.
      • 53. The peptide according to embodiment 49, wherein X32, X33, X34, X35, X36, X37, X38 and X39 are absent.
      • 54. The peptide according to embodiment 49, wherein X30, X31, X32, X33, X34, X35, X36, X37, X38 and X39 are absent.
      • 55. The peptide according to embodiments 49 or 50, wherein X32X33X34X35 is selected from the group of: SSGA (SEQ ID NO.: 40), ESGA (SEQ ID NO.: 41) and SKGA (SEQ ID NO.: 42).
      • 56. The peptide according to embodiment 55, wherein X32X33X34X35 SSGA (SEQ ID NO.: 40).
      • 57. The peptide according to embodiment 55, wherein X32X33X34X35 is ESGA (SEQ ID NO.: 41).
      • 58. The peptide according to embodiment 55, wherein X32X33X34X35 is SKGA (SEQ ID NO.: 42).
      • 59. The peptide according to any one of embodiments 47-58, wherein the peptide has the amide modification of the C-terminus.
      • 60. The peptide according to embodiment 49, wherein the amino acid sequence of the peptide is
  • (SEQ ID NO. : 37)
    YX2EGTX6TSDYSX12X13LEX16QAAX20X21FX23X24WLLX28GGPSSGAPPPS
        • wherein
          • X2 is Aib or A
          • X6 is F or V
          • X12 is I or Y
          • X13 is Y, A, L or I
          • X16 is K or E
          • X20 is Q, R, E, H
          • X21 is A or E
          • X23 is I or V
          • X24 is E, Q or N
          • X28 is A or R.
      • 61. The peptide according to embodiment 48, wherein the amino acid sequence of the peptide is
  • (SEQ ID NO.: 38)
    YX2EGTX6TSDYSX12X13LEX16QAAX20X21FX23X24WLLX28GGPESGAPPPS
        • wherein
          • X2 is Aib or A
          • X6 is F or V
          • X12 is I or Y
          • X13 is Y, A, L or I
          • X16 is K or E
          • X20 is Q, R, E, H
          • X21 is A or E
          • X23 is I or V
          • X24 is E, Q or N
          • X28 is A or R.
      • 62. The peptide according to embodiment 49, wherein the amino acid sequence of the peptide is
  • (SEQ ID NO.: 39)
    YX2EGTX6TSDYSX12X13LEX16QAAX20X21FX23X24WLLX28GGPSKGAPPPS
        • wherein
        • X2 is Aib or A
        • X6 is F or V
        • X12 is I or Y
        • X13 is Y, A, L or I
        • X16 is K or E
        • X20 is Q, R, E, H
        • X21 is A or E
        • X23 is I or V
        • X24 is E, Q or N
        • X28 is A or R
      • 63. The peptide according to embodiment 49 where the amino acid sequence of the peptide is any one of SEQ ID NO.: 1-27 or 33-35.
      • 64. The peptide according to embodiment 63, wherein the peptide has the amide modification of the C-terminus.
      • 65. The peptide according to any of the previous embodiments 49-64, wherein X13LEX16QAAX20X21FX23X24 is selected from the group consisting of:
  • (SEQ ID NO.: 43)
    LLEKQAAREFIN
    (SEQ ID NO.: 44)
    LLEKQAAREFIE,
    (SEQ ID NO.: 45)
    LLEKQAAQEFIE,
    and
    (SEQ ID NO.: 46)
    LLEEQAAREFIE .
      • 66. The peptide according to any of the previous embodiments 49-64, wherein the peptide activates the human GLP-1 and GIP receptors in vitro with an EC50 of less than 20 pM when measured without HSA in a CRE luciferase reporter assays as described in Example 2.
      • 67. The peptide according to any of the previous embodiments 49-64Error! Reference source not found, wherein X16 is K.
      • 68. The peptide according to any of the previous embodiments 49-64, wherein X33 is K.
      • 69. A method for preparing a compound according to any of the previous embodiments 1-40.
      • 70. A method for preparing a peptide according to any of the previous embodiments 49-64.
    METHODS AND EXAMPLES List of Abbreviations
  • The following abbreviations are used in the following, in alphabetical order:
      • Ac: acetyl
      • Ado (also called OEG): 8-amino-3,6-dioxaoctanoic acid
      • Aib: α-aminoisobutyric acid
      • API: active pharmaceutical ingredient
      • AUC: area under the curve
      • BG: blood glucose
      • BHK: baby hamster kidney
      • Boc: tert-butyloxycarbonyl
      • BW: body weight
      • CAS: Chemical Abstracts Service
      • CI-HOBt: 6-chloro-1-hydroxybenzotriazole
      • DCM: dichloromethane
      • DIC: diisopropylcarbodiimide
      • DIPEA: N,N-diisopropylethylamine
      • DMEM: Dulbecco's Modified Eagle's Medium
      • DPBS: Dulbecco's phosphate buffered saline
      • EDTA: ethylenediaminetetraacetic acid
      • ELISA: enzyme linked immunosorbent assay
      • equiv: molar equivalent
      • FBS: fetal bovine serum
      • Fmoc: 9-fluorenylmethyloxycarbonyl
      • GIP: glucose-dependent insulinotropic polypeptide
      • GIPR: glucose-dependent insulinotropic polypeptide receptor
      • GLP-1: glucagon-like peptide 1
      • GLP-1R: glucagon-like peptide 1 receptor
      • h: hours
      • HEPES: 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid
      • HFIP: 1,1,1,3,3,3-hexafluoro-2-propanol or hexafluoroisopropanol
      • HPLC: high performance liquid chromatography
      • HSA: human serum albumin
      • i.p.: intraperitoneal
      • IPGTT: intraperitoneal glucose tolerance test
      • i.v. intravenously
      • LCMS: liquid chromatography mass spectroscopy
      • LYD: Landrace Yorkshire Duroc
      • MeCN: acetonitrile
      • MeOH: methanol
      • mM: millimolar
      • mmol: millimoles
      • min: minutes
      • Mtt: 4-methyltrityl
      • MW: molecular weight
      • nM: nanomolar
      • NMP: 1-methyl-pyrrolidin-2-one
      • OEG: 8-amino-3,6-dioxaoctanoic acid (also called Ado)
      • OtBu: tert-butyl ester
      • Oxyma Puree: cyano-hydroxyimino-acetic acid ethyl ester
      • Pbf: 2,2,4,6,7-pentamethyldihydrobenzofuran-5-sulfonyl
      • PBS: phosphate buffered saline
      • PD: pharmacodynamic
      • PK: pharmacokinetic
      • pM: picomolar
      • RP: reverse phase
      • RP-HPLC: reverse phase high performance liquid chromatography
      • rpm: rounds per minute
      • RT: room temperature
      • Rt: retention time
      • s.c.: subcutaneous
      • SD: standard deviation
      • SEC-HPLC: size exclusion high performance liquid chromatography
      • SEM: standard error of the mean
      • SNAC: sodium N-[8-(2-hydroxybenzoyl)amino]caprylate
      • SPPS: solid phase peptide synthesis
      • tBu: tert-butyl
      • TFA: trifluoroacetic acid
      • TIS: triisopropylsilane
      • Trt: triphenylmethyl or trityl
      • Trx: tranexamic acid
    General Methods of Preparation
  • Methods for solid phase peptide synthesis (SPPS methods, including methods for de-protection of amino acids, methods for cleaving the peptide from the resin, and for its purification), as well as methods for detecting and characterising the resulting peptide (LCMS methods) are described here below.
  • Resins employed for the preparation of C-terminal peptide amides were H-Rink Amide-ChemMatrix resin (loading e.g. 0.5 mmol/g). The Fmoc-protected amino acid derivatives used, unless specifically stated otherwise, were the standard recommended: Fmoc-Ala-OH, Fmoc-Arg(Pbf)-OH, Fmoc-Asn(Trt)-OH, Fmoc-Asp(OtBu)-OH, Fmoc-Cys(Trt)-OH, Fmoc-Gln(Trt)-OH, Fmoc-Glu(OtBu)-OH, Fmoc-Gly-OH, Fmoc-His(Trt)-OH, Fmoc-Ile-OH, Fmoc-Leu-OH, Fmoc-Lys(Boc)-OH, Fmoc-Met-OH, Fmoc-Phe-OH, Fmoc-Pro-OH, Fmoc-Ser(tBu)-OH, Fmoc-Thr(tBu)-OH, Fmoc-Trp(Boc)-OH, Fmoc-Tyr(tBu)-OH, Fmoc-Val-OH, Fmoc-Lys(Mtt)-OH, Fmoc-Aib-OH, etc. supplied from e.g. AAPPTEC, Anaspec, Bachem, Chemlmpex, Iris Biotech, Midwest Biotech, Gyros Protein Technologies or Novabiochem. Where nothing else is specified, the natural L-form of the amino acids are used. The N-terminal amino acid was Boc protected at the alpha-amino group, either by using a reagent with the Boc group pre-installed (e.g. Boc-Tyr(tBu)-OH for peptides with Tyr at the N-terminus) or by exchanging the N-terminal Fmoc protective group for the Boc protective group after installation of the amino acid at the peptide N-terminus.
  • In case of modular albumin binding moiety attachment using SPPS, the following suitably protected building blocks such as but not limited to Fmoc-8-amino-3,6-dioxaoctanoic acid (Fmoc-Ado-OH), Boc-Lys(Fmoc)-OH, Fmoc-Glu-OtBu, hexadecanedioic acid mono-tert-butyl ester, octadecanedioic acid mono-tert-butyl ester, nonadecanedioic acid mono-tert-butyl ester, eicosanedioic acid mono-tert-butyl ester, tetradecanedioic acid mono-tert-butyl ester, or 4-(9-carboxynonyloxy) benzoic acid tert-butyl ester were used. All operations stated below were performed within a 0.1-0.2 mmol synthesis scale range.
  • 1. Synthesis of Resin-Bound Protected Peptide Backbone:
  • Method: SPPS_A
  • SPPS was performed using Fmoc based chemistry on a Protein Technologies SymphonyX solid phase peptide synthesizer, using the manufacturer supplied protocols with minor modifications. Mixing was accomplished by occasional bubbling with nitrogen. The step-wise assembly was performed using the following steps: 1) pre-swelling of resin in DMF; 2) Fmoc-deprotection by the use of 20% (v/v) piperidine in DMF for two treatments of 10 min each; 3) washes with DMF to remove piperidine; 4) coupling of Fmoc-amino acid by the addition of Fmoc-amino acid (12 equiv) and Oxyma Pure® (12 equiv) as a 0.6 M solution each in DMF, followed by addition of DIC (12 equiv) as a 1.2 M solution in DMF, followed by the addition of DMF to reduce the final concentration of each component to 0.3 M, then mixing for 0.5-4 h; 4) washes with DMF to remove excess reagents; 5) final washes with DCM at the completion of the assembly. Some amino acids such as, but not limited to, those following a sterically hindered amino acid (e.g. Aib) were coupled with an extended reaction time (e.g. 4 h) to ensure reaction completion.
  • Method: SPPS_B
  • The protected peptidyl resin was synthesized according to the Fmoc strategy on an Applied Biosystems 431A solid-phase peptide synthesizer using the manufacturer supplied general Fmoc protocols. Mixing was accomplished by vortexing and occasional bubbling with nitrogen. The step-wise assembly was done using the following steps: 1) activation of Fmoc-amino acid by dissolution of solid Fmoc-acid acid (10 equiv) in CI-HOBt (10 equiv) as a 1 M solution in NMP, then addition of DIC (10 equiv) as a 1 M solution in NMP, then mixing simultaneous to steps 2-3; 2) Fmoc-deprotection by the use of 20% (v/v) piperidine in NMP for one treatment of 3 min then a second treatment of 15 min; 3) washes with NMP to remove piperidine; 4) addition of activated Fmoc-amino acid solution to resin, then mixing for 45-90 min; 4) washes with NMP to remove excess reagents; 5) final washes with DCM at the completion of the assembly. The standard protected amino acid derivatives listed above were supplied in pre-weighed cartridges (from e.g. Midwest Biotech), and non-standard derivatives were weighed by hand. Some amino acids such as, but not limited to, those following a sterically hindered amino acid (e.g. Aib) were “double coupled” to ensure reaction completion, meaning that after the first coupling (e.g. 45 min) the resin is drained, more reagents are added (Fmoc-amino acid, DIC, CI-HOBt), and the mixture allowed to react again (e.g. 45 min).
  • Method: SPPS_C
  • SPPS was performed using Fmoc based chemistry on a PreludeX solid phase peptide synthesizer, using the manufacturer supplied protocols with minor modifications. Mixing was accomplished by shaking at 350 rpm and occasional bubbling with nitrogen. The step-wise assembly was performed using the following steps: 1) pre-swelling of resin in DMF; 2) Fmoc-deprotection by the use of 20% (v/v) piperidine in DMF for one treatment of 3 min at 70° C.; 3) washes with DMF to remove piperidine; 4) coupling of Fmoc-amino acid by the addition of Fmoc-amino acid (12 equiv) and Oxyma Pure® (12 equiv) as a 0.4 M solution each in DMF, followed by addition of DIC (12 equiv) as a 1.2 M solution in DMF, then mixing for 5 min at 70° C.; 4) washes with DMF to remove excess reagents; 5) final washes with DCM at the completion of the assembly. Some amino acids such as, but not limited to, those following a sterically hindered amino acid (e.g. Aib) were coupled with an extended reaction time (e.g. 15 min) to ensure reaction completion.
  • 2. Attachment of Substituent to Resin-Bound Protected Peptide Backbone
  • Method: SC_A
  • The N-epsilon-lysine protection Mtt protection group was removed by washing the resin with 30% HFIP in DCM for two treatments of 45 min each, following by washing with DCM and DMF. Acylation was performed on a Protein Technologies SymphonyX solid phase peptide synthesizer using the protocols described in method SPPS_A using stepwise addition of building blocks, such as, but not limited to, Boc-Lys(Fmoc)-OH, Fmoc-8-amino-3,6-dioxaoctanoic acid, Fmoc-Glu-OtBu, hexadecanedioic acid mono-tert-butyl ester, octadecanedioic acid mono-tert-butyl ester, and eicosanedioic acid mono-tert-butyl ester.
  • Method: SC_B
  • The N-epsilon-lysine protection Mtt protection group was removed by washing the resin with 30% HFIP in DCM for two treatments of 45 min each, following by washing with DCM and DMF. Acylation was performed on an Applied Biosystems 431A solid-phase peptide synthesizer using the protocols described in method SPPS_B using stepwise addition of building blocks, such as, but not limited to, Boc-Lys(Fmoc)-OH, Fmoc-8-amino-3,6-dioxaoctanoic acid, Fmoc-Glu-OtBu, hexadecanedioic acid mono-tert-butyl ester, octadecanedioic acid mono-tert-butyl ester, and eicosanedioic acid mono-tert-butyl ester.
  • Method: SC_C
  • The N-epsilon-lysine protection Mtt protection group was removed by washing the resin with 30% HFIP in DCM for two treatments of 45 min each, following by washing with DCM and DMF. Acylation was performed on a Protein Technologies PreludeX solid phase peptide synthesizer using the protocols described in method SPPS_C using stepwise addition of building blocks, such as, but are not limited to, Boc-Lys(Fmoc)-OH, Fmoc-8-amino-3,6-dioxaoctanoic acid, Fmoc-Glu-OtBu, hexadecanedioic acid mono-tert-butyl ester, octadecanedioic acid mono-tert-butyl ester, and eicosanedioic acid mono-tert-butyl ester.
  • 3. Cleavage of Resin Bound Peptide and Purification:
  • Method: CP_A
  • Following completion of the sidechain synthesis, the peptidyl resin was washed with DCM and dried, then treated with TFA/water/TIS (95:2.5:2.5 v/v/v) for approximately 2 h, followed by precipitation with diethyl ether. The precipitate was washed with diethyl ether, dissolved in a suitable solvent (e.g. 2:1 water/MeCN), and let stand until all labile adducts decomposed. Purification was performed by reversed-phase preparative HPLC (Waters 2545 binary gradient module, Waters 2489 UV/Visible detector, Waters fraction collector III) on a Phenomenex Luna C8(2) column (10 μM particle size, 100 Å pore size, 250×21.2 mm dimensions). Separation of impurities and product elution was accomplished using an increasing gradient of MeCN in water containing 0.1% TFA. Relevant fractions were checked for identity and purity by analytical LCMS. Fractions containing the pure desired product were pooled and freeze-dried to afford the peptide TFA salt as a white solid.
  • 4. Salt Exchange from TFA to Sodium Salt:
  • Method: SX_A
  • The freeze-dried peptide isolated from method CP_A was dissolved to 5-20 mg/mL in an appropriate aqueous buffer (e.g. 4:1 water/MeCN, 0.2 M sodium acetate) and adjusted to pH 7-8 with 1 M NaOH if necessary to achieve full solubility. The buffered solutions containing the peptide were salt-exchanged using a Sep-Pak C18 cartridge (0.5-2 g): The cartridge was first equilibrated with 4 column volumes of isopropanol, then 4 column volumes of MeCN, then 8 column volumes of water. The peptide solution was applied to the cartridge, and the flow through was reapplied to ensure complete retention of peptide. The cartridge was washed with 4 column volumes of water, then 10 column volumes of a buffer solution (e.g. pH 7.5) containing such as, but not limited to, NaHCO3, NaOAc, or Na2HPO4. The column was washed with 4 column volumes of water, and the peptide was eluted with 5-10 column volumes of 50-80% MeCN in water. The peptide-containing eluent was freeze-dried to afford the peptide sodium salt as a white solid, which was used as such.
  • General Methods of Detection and Characterisation
  • LCMS Methods:
  • Method: LCMS_A
  • LCMS_A was performed on a setup consisting of an Agilent 1260 Infinity series HPLC system and an Agilent Technologies 6120 Quadrupole MS. Eluents: A: 0.05% TFA in water; B: 0.05% TFA in 9:1 MeCN/water.
  • The analysis was performed at RT (column temp 37C) by injecting an appropriate volume of the sample onto the column which was eluted with a gradient of A and B. Column: Phenomenex Kinetex C8, 2.6 μm, 100 Å, 4.6×75 mm. Gradient run time: Linear 10-80% B over 10 min at a flow rate of 1.0 mL/min. Detection: diode array detector set to 214 nm. MS ionisation mode: API-ES, positive polarity. MS scan mass range: 500-2000 amu.
    • Method: LCMS_B
  • LCMS_B was performed on a setup consisting of an Agilent 1260 Infinity series HPLC system and an Agilent Technologies 6120 Quadrupole MS. Eluents: A: 0.05% TFA in water; B: 0.05% TFA in 9:1 MeCN/water.
  • The analysis was performed at RT (column temp 37C) by injecting an appropriate volume of the sample onto the column which was eluted with a gradient of A and B. Column: Phenomenex Kinetex C8, 2.6 μm, 100 Å, 4.6×75 mm. Gradient run time: Linear 20-100% B over 10 min at a flow rate of 1.0 mL/min. Detection: diode array detector set to 214 nm. MS ionisation mode: API-ES, positive polarity. MS scan mass range: 500-2000 amu
  • While certain features of the invention have been illustrated and described herein, many modifications, substitutions, changes, and equivalents will now occur to those of ordinary skill in the art. It is, therefore, to be understood that the appended embodiments are intended to cover all such modifications and changes as fall within the true spirit of the invention.
    • Example 1: Synthesis of Compounds
  • The compounds are in the following described using single letter amino acid codes, except for Aib. The substituent is included after the lysine (K) residue to which it is attached.
  • Compound No. 1
  • Y-Aib-EGTFTSDYSIYLE-K[(2S)-2-amino-6-[[(2S)-2-amino-6-[[(4S)-4-carboxy-4-(19-carboxynonadecanoylamino)butanoyl]amino]hexanoyl]amino]hexanoyl]-QAAQEFVNWLLAGGPSSGAPPPS-NH2
  • Figure US20230120597A1-20230420-C00070
  • SEQ ID NO: 1 with C-terminal amide modification; Substituent: C; Substituent position: K16
  • Synthesis methods: SPPS_A; SC_B; CP_A
  • Molecular weight (average) calculated: 4873.5 Da
  • LCMS_A: Rt=6.0 min; found [M+3H]3+ 1625.4, [M+4H]4+ 1219.1.
  • Compound No. 2
  • Y-Aib-EGTFTSDYSYYLE-K[(2S)-2-amino-6-[[(2S)-2-amino-6-[[(4S)-4-carboxy-4-(19-carboxynonadecanoylamino)butanoyl]amino]hexanoyl]amino]hexanoyl]-QAAQEFVNWLLAGGPSSGAPPPS-NH2
  • Figure US20230120597A1-20230420-C00071
  • SEQ ID NO: 2 with C-terminal amide modification; Substituent: C; Substituent position: K16
  • Synthesis methods: SPPS_A; SC_B; CP_A
  • Molecular weight (average) calculated: 4923.5 Da
  • LCMS_A: Rt=6.0 min; found [M+3H]3+ 1641.8, [M+4H]4+ 1237.5
  • Compound No. 3
  • Y-Aib-EGTFTSDYSYYLE-K[(2S)-2-amino-6-[[(2S)-2-amino-6-[[(4S)-4-carboxy-4-(17-carboxyheptadecanoylamino)butanoyl]amino]hexanoyl]amino]hexanoyl]-QAAQEFVNWLLAGGPSSGAPPPS-NH2
  • Figure US20230120597A1-20230420-C00072
  • SEQ ID NO: 2 with C-terminal amide modification; Substituent: B; Substituent position: K16
  • Synthesis methods: SPPS_A; SC_B; CP_A
  • Molecular weight (average) calculated: 4895.4 Da
  • LCMS_A: Rt=5.7 min; found [M+3H]3+ 1632.7, [M+4H]4+ 1224.6
  • Compound No. 4
  • Y-Aib-EGTFTSDYSYYLE-K[(2S)-2-amino-6-[[(2S)-2-amino-6-[[(4S)-4-carboxy-4-(17-carboxyheptadecanoylamino)butanoyl]amino]hexanoyl]amino]hexanoyl]-QAAQAFVNWLLAGGPSSGAPPPS-NH2
  • Figure US20230120597A1-20230420-C00073
  • SEQ ID NO: 3 with C-terminal amide modification; Substituent: B; Substituent position: K16
  • Synthesis methods: SPPS_A; SC_B; CP_A
  • Molecular weight (average) calculated: 4837.4 Da
  • LCMS_A: Rt=5.7 min; found [M+3H]3+ 1613.3, [M+4H]4+ 1210.1
  • Compound No. 5
  • Y-Aib-EGTFTSDYSYYLE-K[(2S)-2-amino-6-[[(2S)-2-amino-6-[[(4S)-4-carboxy-4-(17-carboxyheptadecanoylamino)butanoyl]amino]hexanoyl]amino]hexanoyl]-QAAQAFVNWLLAGGPSSGAPPPS-OH
  • Figure US20230120597A1-20230420-C00074
  • SEQ ID NO: 3; Substituent: B; Substituent position: K16
  • Synthesis methods: SPPS_B; SC_B; CP_A
  • Molecular weight (average) calculated: 4838.4 Da
  • LCMS_A: Rt=5.7 min; found [M+3H]3+ 1613.6, [M+4H]4+ 1210.4
  • Compound No. 6
  • Y-Aib-EGTFTSDYSIYLE-K[(2S)-2-amino-6-[[(2S)-2-amino-6-[[(4S)-4-carboxy-4-(17-carboxyheptadecanoylamino)butanoyl]amino]hexanoyl]amino]hexanoyl]-QAAREFVNWLLAGGPSSGAPPPS-NH2
  • Figure US20230120597A1-20230420-C00075
  • SEQ ID NO: 4 with C-terminal amide modification; Substituent: B; Substituent position: K16
  • Synthesis methods: SPPS_B; SC_B; CP_A
  • Molecular weight (average) calculated: 4873.5 Da
  • LCMS_A: Rt=5.6 min; found [M+3H]3+ 1625.3, [M+4H]4+ 1219.1
  • Compound No. 7
  • Y-Aib-EGTFTSDYSIYLE-K[2-[2-[2-[[2-[2-[2-[[(4S)-4-carboxy-4-(17-carboxyheptadecanoylamino)butanoyl]amino]ethoxy]ethoxy]acetyl]amino]ethoxy]ethoxy] acetyl]-QAAREFVNWLLAGGPSSGAPPPS-NH2
  • Figure US20230120597A1-20230420-C00076
  • SEQ ID NO: 4 with C-terminal amide modification; Substituent: A; Substituent position: K16
  • Synthesis methods: SPPS_B; SC_B; CP_A
  • Molecular weight (average) calculated: 4907.4 Da
  • LCMS_A: Rt=6.3 min; found[M+3H]3+ 1636.5, [M+4H]4+ 1227.9
  • Compound No. 8
  • Y-Aib-EGTFTSDYSIYLE-K[(2S)-2-amino-6-[[(2S)-2-amino-6-[[(4S)-4-carboxy-4-(17-carboxyheptadecanoylamino)butanoyl]amino]hexanoyl]amino]hexanoyl]-QAAREFINWLLAGGPSSGAPPPS-NH2
  • Figure US20230120597A1-20230420-C00077
  • SEQ ID NO: 5 with C-terminal amide modification; Substituent: B; Substituent position: K16
  • Synthesis methods: SPPS_A; SC_A; CP_A
  • Molecular weight (average) calculated: 4887.5 Da
  • LCMS_A: Rt=5.7 min; found [M+3H]3+ 1629.8, [M+4H]4+ 1222.8
  • Compound No. 9
  • Y-Aib-EGTFTSDYSIYLE-K[(2S)-2-amino-6-[[(2S)-2-amino-6-[[(4S)-4-carboxy-4-(17-carboxyheptadecanoylamino)butanoyl]amino]hexanoyl]amino]hexanoyl]-QAAREFIEWLLAGGPSSGAPPPS-OH
  • Figure US20230120597A1-20230420-C00078
  • SEQ ID NO: 6; Substituent: B; Substituent position: K16
  • Synthesis methods: SPPS_A; SC_B; CP_A
  • Molecular weight (average) calculated: 4903.5 Da
  • LCMS_A: Rt=5.8 min; found [M+3H]3+ 1635.2, [M+4H]4+ 1226.8
  • Compound No. 10
  • Y-Aib-EGTFTSDYSIYLE-K[2-[2-[2-[[2-[2-[2-[[(4S)-4-carboxy-4-(17-carboxyheptadecanoylamino)butanoyl]amino]ethoxy]ethoxy]acetyl]amino]ethoxy]ethoxy] acetyl]-QAAREFIEWLLAGGPSSGAPPPS-OH
  • Figure US20230120597A1-20230420-C00079
  • SEQ ID NO: 6; Substituent: A; Substituent position: K16
  • Synthesis methods: SPPS_A; SC_B; CP_A
  • Molecular weight (average) calculated: 4937.5 Da
  • LCMS_A: Rt=6.5 min; found [M+3H]3+ 1646.6, [M+4H]4+ 1235.1
  • Compound No. 11
  • Y-Aib-EGTFTSDYSIYLE-K[(2S)-2-amino-6-[[(2S)-2-amino-6-[[(4S)-4-carboxy-4-(17-carboxyheptadecanoylamino)butanoyl]amino]hexanoyl]amino]hexanoyl]-QAAREFINWLLAGGPSSGAPPPS-OH
  • Figure US20230120597A1-20230420-C00080
  • SEQ ID NO: 5; Substituent: B; Substituent position: K16
  • Synthesis methods: SPPS_A; SC_C; CP_A
  • Molecular weight (average) calculated: 4888.5 Da
  • LCMS_A: Rt=5.7 min; found [M+3H]3+ 1630.2, [M+4H]4+ 1222.9
  • Compound No. 12
  • Y-Aib-EGTFTSDYSIYLE-K[(2S)-2-amino-6-[[(2S)-2-amino-6-[[(4S)-4-carboxy-4-(17-carboxyheptadecanoylamino)butanoyl]amino]hexanoyl]amino]hexanoyl]-QAAREFIEWLLRGGPSSGAPPPS-OH
  • Figure US20230120597A1-20230420-C00081
  • Synthesis methods: SPPS_A; SC_C; CP_A
  • SEQ ID NO: 7; Substituent: B; Substituent position: K16
  • Molecular weight (average) calculated: 4988.6 Da
  • LCMS_A: Rt=5.7 min; found [M+3H]3+ 1663.6, [M+4H]4+ 1248.0
  • Compound No. 13
  • Y-Aib-EGTFTSDYSIYLE-K[(2S)-2-amino-6-[[(2S)-2-amino-6-[[(4S)-4-carboxy-4-(17-carboxyheptadecanoylamino)butanoyl]amino]hexanoyl]amino]hexanoyl]-QAAREFIEWLLRGGPESGAPPPS-OH
  • Figure US20230120597A1-20230420-C00082
  • SEQ ID NO: 8; Substituent: B; Substituent position: K16
  • Synthesis methods: SPPS_A; SC_C; CP_A
  • Molecular weight (average) calculated: 5030.6 Da
  • LCMS_A: Rt=5.7 min; found [M+3H]3+ 1677.7, [M+4H]4+ 1258.4
  • Compound No. 14
  • Y-Aib-EGTFTSDYSIALE-K[(2S)-2-amino-6-[[(2S)-2-amino-6-[[(4S)-4-carboxy-4-(17-carboxyheptadecanoylamino)butanoyl]amino]hexanoyl]amino]hexanoyl]-QAAREFINWLLAGGPSSGAPPPS-OH
  • Figure US20230120597A1-20230420-C00083
  • SEQ ID NO: 9; Substituent: B; Substituent position: K16
  • Synthesis methods: SPPS_A; SC_C; CP_A
  • Molecular weight (average) calculated: 4796.4 Da
  • LCMS_A: Rt=5.7 min; found [M+3H]3+ 1599.6, [M+4H]4+ 1199.8
  • Compound No. 15
  • Y-Aib-EGTFTSDYSILLE-K[(2S)-2-amino-6-[[(2S)-2-amino-6-[[(4S)-4-carboxy-4-(17-carboxyheptadecanoylamino)butanoyl]amino]hexanoyl]amino]hexanoyl]-QAAREFINWLLAGGPSSGAPPPS-OH
  • Figure US20230120597A1-20230420-C00084
  • SEQ ID NO: 10; Substituent: B; Substituent position: K16
  • Synthesis methods: SPPS_A; SC_A; CP_A; SX_A
  • Molecular weight (average) calculated: 4838.5 Da
  • LCMS_A: Rt=5.8 min; found [M+3H]3+ 1613.4, [M+4H]4+ 1210.3
  • Compound No. 16
  • Y-Aib-EGTFTSDYSIYLE-K[(2S)-2-amino-6-[[(2S)-2-amino-6-[[(4S)-4-carboxy-4-(19-carboxynonadecanoylamino)butanoyl]amino]hexanoyl]amino]hexanoyl]-QAAREFINWLLAGGPSSGAPPPS-OH
  • Figure US20230120597A1-20230420-C00085
  • SEQ ID NO: 5; Substituent: C; Substituent position: K16
  • Synthesis methods: SPPS_A; SC_A; CP_A
  • Molecular weight (average) calculated: 4916.5 Da
  • LCMS_A: Rt=6.0 min; found [M+3H]3+ 1639.6, [M+4H]4+ 1229.9
  • Compound No. 17
  • YAEGTFTSDYSIYLE-K[(2S)-2-amino-6-[[(2S)-2-amino-6-[[(4S)-4-carboxy-4-(17-carboxyheptadecanoylamino)butanoyl]amino]hexanoyl]amino]hexanoyl]-QAAREFINWLLAGGPSSGAPPPS-OH
  • Figure US20230120597A1-20230420-C00086
  • SEQ ID NO: 11; Substituent: B; Substituent position: K16
  • Synthesis methods: SPPS_C; SC_A; CP_A
  • Molecular weight (average) calculated: 4874.5 Da
  • LCMS_A: Rt=5.7 min; found [M+3H]3+ 1625.4, [M+4H]4+ 1219.4
  • Compound No. 18
  • Y-Aib-EGTFTSDYSILLE-K[(2S)-2-amino-6-[[(2S)-2-amino-6-[[(4S)-4-carboxy-4-(17-carboxyheptadecanoylamino)butanoyl]amino]hexanoyl]amino]hexanoyl]-QAAREFINWLLAG-OH
  • Figure US20230120597A1-20230420-C00087
  • SEQ ID NO: 12; Substituent: B; Substituent position: K16
  • Synthesis methods: SPPS_A; SC_A; CP_A
  • Molecular weight (average) calculated: 4003.6 Da
  • LCMS_A: Rt=6.2 min; found [M+3H]3+ 1335.3, [M+4H]4+ 1001.7
  • Compound No. 19
  • Y-Aib-EGTFTSDYSILLE-K[(2S)-2-amino-6-[[(2S)-2-amino-6-[[(4S)-4-carboxy-4-(17-carboxyheptadecanoylamino)butanoyl]amino]hexanoyl]amino]hexanoyl]-QAAREFINWLLAGGP-OH
  • Figure US20230120597A1-20230420-C00088
  • SEQ ID NO: 13; Substituent: B; Substituent position: K16
  • Synthesis methods: SPPS_A; SC_A; CP_A
  • Molecular weight (average) calculated: 4157.8 Da
  • LCMS_A: Rt=6.1 min; found [M+3H]3+ 1386.6, [M+4H]4+ 1040.3
  • Compound No. 20
  • Y-Aib-EGTFTSDYSILLE-K[(2S)-2-amino-6-[[(2S)-2-amino-6-[[(4S)-4-carboxy-4-(17-carboxyheptadecanoylamino)butanoyl]amino]hexanoyl]amino]hexanoyl]-QAAREFINWLLAGGPSS-OH
  • Figure US20230120597A1-20230420-C00089
  • SEQ ID NO: 14; Substituent: B; Substituent position: K16
  • Synthesis methods: SPPS_A; SC_A; CP_A
  • Molecular weight (average) calculated: 4331.9 Da
  • LCMS_A: Rt=5.9 min; found [M+3H]3+ 1444.7, [M+4H]4+ 1083.7
  • Compound No. 21
  • Y-Aib-EGTFTSDYSILLE-K[(2S)-2-amino-6-[[(2S)-2-amino-6-[[(4S)-4-carboxy-4-(17-carboxyheptadecanoylamino)butanoyl]amino]hexanoyl]amino]hexanoyl]-QAAR-EFINWLLAGGPSSGA-OH
  • Figure US20230120597A1-20230420-C00090
  • SEQ ID NO: 15; Substituent: B; Substituent position: K16
  • Synthesis methods: SPPS_A; SC_A; CP_A
  • Molecular weight (average) calculated: 4460.0 Da
  • LCMS_A: Rt=5.9 min; found [M+3H]3+ 1487.5, [M+4H]4+ 1116.1
  • Compound No. 22
  • Y-Aib-EGTFTSDYSILLE-K[(2S)-2-amino-6-[[(2S)-2-amino-6-[[(4S)-4-carboxy-4-(17-carboxyheptadecanoylamino)butanoyl]amino]hexanoyl]amino]hexanoyl]-QAAREFVNWLLAGGPSSGAPPPS-OH
  • Figure US20230120597A1-20230420-C00091
  • SEQ ID NO: 16; Substituent: B; Substituent position: K16
  • Synthesis methods: SPPS_A; SC_A; CP_A
  • Molecular weight (average) calculated: 4824.4 Da
  • LCMS_A: Rt=5.7 min; found [M+3H]3+ 1608.9, [M+4H]4+ 1206.9
  • Compound No. 23
  • Y-Aib-EGTFTSDYSILLE-K[(2S)-2-amino-6-[[(2S)-2-amino-6-[[(4S)-4-carboxy-4-(17-carboxyheptadecanoylamino)butanoyl]amino]hexanoyl]amino]hexanoyl]-QAAREFIQWLLAGGPSSGAPPPS-OH
  • Figure US20230120597A1-20230420-C00092
  • SEQ ID NO: 17; Substituent: B; Substituent position: K16
  • Synthesis methods: SPPS_A; SC_A; CP_A
  • Molecular weight (average) calculated: 4852.5 Da
  • LCMS_A: Rt=5.9 min; found [M+3H]3+ 1618.4, [M+4H]4+ 1214.1
  • Compound No. 24
  • Y-Aib-EGTFTSDYSILLE-K[(2S)-2-amino-6-[[(2S)-2-amino-6-[[(4S)-4-carboxy-4-(17-carboxyheptadecanoylamino)butanoyl]amino]hexanoyl]amino]hexanoyl]-QAAQEFINWLLAGGPSSGAPPPS-OH
  • Figure US20230120597A1-20230420-C00093
  • SEQ ID NO: 18; Substituent: B; Substituent position: K16
  • Synthesis methods: SPPS_A; SC_C; CP_A
  • Molecular weight (average) calculated: 4810.4 Da
  • LCMS_A: Rt=6.0 min; found [M+3H]3+ 1604.0, [M+4H]4+ 1203.4
  • Compound No. 25
  • Y-Aib-EGTFTSDYSILLE-K[(2S)-2-amino-6-[[(2S)-2-amino-6-[[(4S)-4-carboxy-4-(17-carboxyheptadecanoylamino)butanoyl]amino]hexanoyl]amino]hexanoyl]-QAAEEFINWLLAGGPSSGAPPPS-OH
  • Figure US20230120597A1-20230420-C00094
  • SEQ ID NO: 19; Substituent: B; Substituent position: K16
  • Synthesis methods: SPPS_A; SC_C; CP_A
  • Molecular weight (average) calculated: 4811.4 Da
  • LCMS_A: Rt=6.1 min; found [M+3H]3+ 1604.4, [M+4H]4+ 1203.6
  • Compound No. 26
  • Y-Aib-EGTFTSDYSILLE-K[(2S)-2-amino-6-[[(2S)-2-amino-6-[[(4S)-4-carboxy-4-(17-carboxyheptadecanoylamino)butanoyl]amino]hexanoyl]amino]hexanoyl]-QAAHEFINWLLAGGPSSGAPPPS-OH
  • Figure US20230120597A1-20230420-C00095
  • SEQ ID NO: 20; Substituent: B; Substituent position: K16
  • Synthesis methods: SPPS_A; SC_C; CP_A
  • Molecular weight (average) calculated: 4819.4 Da
  • LCMS_A: Rt=5.8 min; found [M+3H]3+ 1607.1, [M+4H]4+ 1205.5
  • Compound No. 27
  • Y-Aib-EGTFTSDYSILLE-K[(2S)-2-amino-6-[[(2S)-2-amino-6-[[(4S)-4-carboxy-4-(17-carboxyheptadecanoylamino)butanoyl]amino]hexanoyl]amino]hexanoyl]-QAAREFIEWLLRGGPSSGAPPPS-OH
  • Figure US20230120597A1-20230420-C00096
  • SEQ ID NO: 21; Substituent: B; Substituent position: K16
  • Synthesis methods: SPPS_A; SC_C; CP_A
  • Molecular weight (average) calculated: 4938.6 Da
  • LCMS_A: Rt=5.7 min; found [M+3H]3+ 1646.9, [M+4H]4+ 1235.4
  • Compound No. 28
  • Y-Aib-EGTFTSDYSILLE-K[(2S)-2-amino-6-[[(2S)-2-amino-6-[[(4S)-4-carboxy-4-(17-carboxyheptadecanoylamino)butanoyl]amino]hexanoyl]amino]hexanoyl]-QAAREFIEWLLRGGPESGAPPPS-OH
  • Figure US20230120597A1-20230420-C00097
  • SEQ ID NO: 22; Substituent: B; Substituent position: K16
  • Synthesis methods: SPPS_A; SC_A; CP_A; SX_A
  • Molecular weight (average) calculated: 4980.6 Da
  • LCMS_A: Rt=5.8 min; found [M+3H]3+ 1660.7, [M+4H]4+ 1246.0
  • Compound No. 29
  • Y-Aib-EGTFTSDYSILLE-K[(2S)-2-amino-6-[[(2S)-2-amino-6-[[(4S)-4-carboxy-4-(17-carboxyheptadecanoylamino)butanoyl]amino]hexanoyl]amino]hexanoyl]-QAAQEFIEWLLAGGPSSGAPPPS-OH
  • Figure US20230120597A1-20230420-C00098
  • SEQ ID NO: 23; Substituent: B; Substituent position: K16
  • Synthesis methods: SPPS_A; SC_A; CP_A; SX_A
  • Molecular weight (average) calculated: 4825.4 Da
  • LCMS_A: Rt=6.1 min; found [M+3H]3+ 1609.3, [M+4H]4+ 1207.0
  • Compound No. 30
  • Y-Aib-EGTFTSDYSILLE-K[(2S)-2-amino-6-[[(2S)-2-amino-6-[[(4S)-4-carboxy-4-(17-carboxyheptadecanoylamino)butanoyl]amino]hexanoyl]amino]hexanoyl]-QAAHEFIEWLLAGGPSSGAPPPS-OH
  • Figure US20230120597A1-20230420-C00099
  • SEQ ID NO: 24; Substituent: B; Substituent position: K16
  • Synthesis methods: SPPS_A; SC_A; CP_A
  • Molecular weight (average) calculated: 4834.4 Da
  • LCMS_A: Rt=5.8 min; found [M+3H]3+ 1612.1, [M+4H]4+ 1209.3
  • Compound No. 31
  • Y-Aib-EGTFTSDYSILLE-K[(2S)-2-amino-6-[[(2S)-2-amino-6-[[(4S)-4-carboxy-4-(17-carboxyheptadecanoylamino)butanoyl]amino]hexanoyl]amino]hexanoyl]-QAAREFIEWLLAGGPSSGAPPPS-OH
  • Figure US20230120597A1-20230420-C00100
  • SEQ ID NO: 25; Substituent: B; Substituent position: K16
  • Synthesis methods: SPPS_A; SC_A; CP_A; SX_A
  • Molecular weight (average) calculated: 4853.5 Da
  • LCMS_A: Rt=5.9 min; found [M+3H]3+ 1618.5, [M+4H]4+ 1214.2
  • Compound No. 32
  • Y-Aib-EGTFTSDYSILLE-K[2-[2-[2-[[2-[2-[2-[[(4S)-4-carboxy-4-(17-carboxyheptadecanoylamino)butanoyl]amino]ethoxy]ethoxy]acetyl]amino]ethoxy]ethoxy] acetyl]-QAAREFIEWLLAGGPSSGAPPPS-OH
  • Figure US20230120597A1-20230420-C00101
  • SEQ ID NO: 25; Substituent: A; Substituent position: K16
  • Synthesis methods: SPPS_A; SC_A; CP_A
  • Molecular weight (average) calculated: 4887.4 Da
  • LCMS_A: Rt=6.6 min; found [M+3H]3+ 1629.8, [M+4H]4+ 1222.8
  • Compound No. 33
  • Y-Aib-EGTVTSDYSILLE-K[(2S)-2-amino-6-[[(2S)-2-amino-6-[[(4S)-4-carboxy-4-(17-carboxyheptadecanoylamino)butanoyl]amino]hexanoyl]amino]hexanoyl]-QAAREFINWLLAGGPSSGAPPPS-OH
  • Figure US20230120597A1-20230420-C00102
  • SEQ ID NO: 26; Substituent: B; Substituent position: K16
  • Synthesis methods: SPPS_A; SC_A; CP_A
  • Molecular weight (average) calculated: 4790.4 Da
  • LCMS_A: Rt=5.8 min; found [M+3H]3+ 1597.4, [M+4H]4+ 1198.3
  • Compound No. 34
  • Y-Aib-EGTFTSDYSIILE-K[(2S)-2-amino-6-[[(2S)-2-amino-6-[[(4S)-4-carboxy-4-(17-carboxyheptadecanoylamino)butanoyl]amino]hexanoyl]amino]hexanoyl]-QAAREFINWLLAGGPSSGAPPPS-OH
  • Figure US20230120597A1-20230420-C00103
  • SEQ ID NO: 27; Substituent: B; Substituent position: K16
  • Synthesis methods: SPPS_A; SC_A; CP_A
  • Molecular weight (average) calculated: 4838.5 Da
  • LCMS_A: Rt=5.8 min; found [M+3H]3+ 1613.4, [M+4H]4+ 1210.3
  • Compound No. 35
  • Y-Aib-EGTFTSDYSILLE-K[2-[2-[2-[[2-[2-[2-[[(4S)-4-carboxy-4-(17-carboxyheptadecanoylamino)butanoyl]amino]ethoxy]ethoxy]acetyl]amino]ethoxy]ethoxy] acetyl]-QAAREFINWLLAGGPSSGAPPPS-OH
  • Figure US20230120597A1-20230420-C00104
  • SEQ ID NO: 10; Substituent: A; Substituent position: K16
  • Synthesis methods: SPPS_A; SC_A; CP_A
  • Molecular weight (average) calculated: 4872.4 Da
  • LCMS_A: Rt=6.6 min; found [M+3H]3+ 1624.9, [M+4H]4+ 1218.9
  • Compound No. 36
  • Y-Aib-EGTFTSDYSIILE-K[2-[2-[2-[[2-[2-[2-[[(4S)-4-carboxy-4-(17-carboxyheptadecanoylamino)butanoyl]amino]ethoxy]ethoxy]acetyl]amino]ethoxy]ethoxy] acetyl]-QAAREFINWLLAGGPSSGAPPPS-OH
  • Figure US20230120597A1-20230420-C00105
  • SEQ ID NO: 27; Substituent: A; Substituent position: K16
  • Synthesis methods: SPPS_A; SC_A; CP_A
  • Molecular weight (average) calculated: 4872.4 Da
  • LCMS_A: Rt=6.5 min; found [M+3H]3+ 1624.8, [M+4H]4+ 1218.9
  • Compound No. 37
  • Y-Aib-EGTFTSDYSIYLEEQAAR-K[(2S)-2-amino-6-[[(2S)-2-amino-6-[[(4S)-4-carboxy-4-(17-carboxyheptadecanoylamino)butanoyl]amino]hexanoyl]amino]hexanoyl]-FINWLLAGGPSSGAPPPS-OH
  • Figure US20230120597A1-20230420-C00106
  • SEQ ID NO: 28; Substituent: B; Substituent position: K21
  • Synthesis methods: SPPS_A; SC_C; CP_A
  • Molecular weight (average) calculated: 4888.5 Da
  • LCMS_A: Rt=6.0 min; found [M+3H]3+ 1630.3, [M+4H]4+ 1223.0
  • Compound No. 38
  • Y-Aib-EGTFTSDYSIYLEE-K[(2S)-2-amino-6-[[(2S)-2-amino-6-[[(4S)-4-carboxy-4-(17-carboxyheptadecanoylamino)butanoyl]amino]hexanoyl]amino]hexanoyl]-AAREFINWLLAGGPSSGAPPPS-OH
  • Figure US20230120597A1-20230420-C00107
  • SEQ ID NO: 29; Substituent: B; Substituent position: K17
  • Synthesis methods: SPPS_C; SC_C; CP_A
  • Molecular weight (average) calculated: 4889.5 Da
  • LCMS_A: Rt=6.0 min; found [M+3H]3+ 1630.6, [M+4H]4+ 1223.2
  • Compound No. 39
  • Y-Aib-EGTFTSDYSILLEEQAAR-K[(2S)-2-amino-6-[[(2S)-2-amino-6-[[(4S)-4-carboxy-4-(17-carboxyheptadecanoylamino)butanoyl]amino]hexanoyl]amino]hexanoyl]-FINWLLAGGPSSGAPPPS-OH
  • Figure US20230120597A1-20230420-C00108
  • SEQ ID NO: 30; Substituent: B; Substituent position: K21
  • Synthesis methods: SPPS_A; SC_C; CP_A
  • Molecular weight (average) calculated: 4838.5 Da
  • LCMS_A: Rt=6.2 min; found [M+3H]3+ 1613.5, [M+4H]4+ 1210.4
  • Compound No. 40
  • Y-Aib-EGTFTSDYS-K[(2S)-2-amino-6-[[(2S)-2-amino-6-[[(4S)-4-carboxy-4-(17-carboxyheptadecanoylamino)butanoyl]amino]hexanoyl]amino]hexanoyl]-LLEEQAAREFIEWLLAGGPSSGAPPPS-OH
  • Figure US20230120597A1-20230420-C00109
  • SEQ ID NO: 31; Substituent: B; Substituent position: K12
  • Synthesis methods: SPPS_A; SC_A; CP_A
  • Molecular weight (average) calculated: 4869.4 Da
  • LCMS_A: Rt=5.7 min; found [M+3H]3+ 1623.8, [M+4H]4+ 1218.2
  • Compound No. 41
  • Y-Aib-EGTFTSDYS-K[(2S)-2-amino-6-[[(2S)-2-amino-6-[[(4S)-4-carboxy-4-(17-carboxyheptadecanoylamino)butanoyl]amino]hexanoyl]amino]hexanoyl]-YLEEQAAREFINWLLAGGPSSGAPPPS-OH
  • Figure US20230120597A1-20230420-C00110
  • SEQ ID NO: 32; Substituent: B; Substituent position: K12
  • Synthesis methods: SPPS_A; SC_A; CP_A
  • Molecular weight (average) calculated: 4904.4 Da
  • LCMS_A: Rt=5.7 min; found [M+3H]3+ 1635.4, [M+4H]4+ 1226.7
  • Compound No. 42
  • Y-Aib-EGTFTSDYSIYLEEQAAREFINWLLAGGPS-K[(2S)-2-amino-6-[[(2S)-2-amino-6-[[(4S)-4-carboxy-4-(17-carboxyheptadecanoylamino)butanoyl]amino]hexanoyl]amino]hexanoyl]-GAPPPS-OH
  • Figure US20230120597A1-20230420-C00111
  • SEQ ID NO: 33; Substituent: B; Substituent position: K33
  • Synthesis methods: SPPS_A; SC_A; CP_A
  • Molecular weight (average) calculated: 4930.5 Da
  • LCMS_A: Rt=6.2 min; found [M+3H]3+ 1644.2, [M+4H]4+ 1233.4
  • Compound No. 43
  • Y-Aib-EGTFTSDYSILLEEQAAREFIEWLLAGGPS-K[(2S)-2-amino-6-[[(2S)-2-amino-6-[[(4S)-4-carboxy-4-(17-carboxyheptadecanoylamino)butanoyl]amino]hexanoyl]amino]hexanoyl]-GAPPPS-OH
  • Figure US20230120597A1-20230420-C00112
  • SEQ ID NO: 34; Substituent: B; Substituent position: K33
  • Synthesis methods: SPPS_A; SC_A; CP_A
  • Molecular weight (average) calculated: 4895.5 Da
  • LCMS_A: Rt=6.3 min; found [M+3H]3+ 1632.4, [M+4H]4+ 1224.6
  • Compound No. 44
  • Y-Aib-EGTFTSDYSILLEEQAAREFINWLLAGGPS-K[(2S)-2-amino-6-[[(2S)-2-amino-6-[[(4S)-4-carboxy-4-(17-carboxyheptadecanoylamino)butanoyl]amino]hexanoyl]amino]hexanoyl]-GAPPPS-OH
  • Figure US20230120597A1-20230420-C00113
  • SEQ ID NO: 35; Substituent: B; Substituent position: K33
  • Synthesis methods: SPPS_A; SC_A; CP_A
  • Molecular weight (average) calculated: 4880.5 Da
  • LCMS_A: Rt=6.2 min; found [M+3H]3+ 1627.5, [M+4H]4+ 1220.9
  • Compound No. 45
  • Y-Aib-EGTFTSDYSILLEEQAAREFIEWLLAGGPS-K[2-[2-[2-[[2-[2-[2-[[(4S)-4-carboxy-4-(17-carboxyheptadecanoylamino)butanoyl]amino]ethoxy]ethoxy]acetyl]amino]ethoxy]ethoxy] acetyl]-GAPPPS-OH
  • Figure US20230120597A1-20230420-C00114
  • SEQ ID NO: 34; Substituent: A; Substituent position: K33
  • Synthesis methods: SPPS_A; SC_A; CP_A
  • Molecular weight (average) calculated: 4929.5 Da
  • LCMS_A: Rt=6.6 min; found [M+3H]3+ 1643.8, [M+4H]4+ 1233.1
  • Compound No. 46
  • Y-Aib-EGTFTSDYSILLEEQAAREFIEWLLAGGPS-K[(2S)-2-amino-6-[[(2S)-2-amino-6-[[(4S)-4-carboxy-4-(15-carboxypentadecanoylamino)butanoyl]amino]hexanoyl]amino]hexanoyl]-GAPPPS-OH
  • Figure US20230120597A1-20230420-C00115
  • SEQ ID NO: 34; Substituent: E; Substituent position: K33
  • Synthesis methods: SPPS_A; SC_A; CP_A
  • Molecular weight (average) calculated: 4867.5 Da
  • LCMS_A: Rt=6.1 min; found [M+3H]3+ 1623.1, [M+4H]4+ 1217.6
  • Compound No. 47
  • Y-Aib-EGTFTSDYSILLEEQAAREFIEWLLAGGPS-K[2-[2-[2-[[2-[2-[2-[[(4S)-4-carboxy-4-(15-carboxypentadecanoylamino)butanoyl]amino]ethoxy]ethoxy]acetyl]amino]ethoxy]ethoxy] acetyl]-GAPPPS-OH
  • Figure US20230120597A1-20230420-C00116
  • SEQ ID NO: 34; Substituent: D; Substituent position: K33
  • Synthesis methods: SPPS_A; SC_A; CP_A
  • Molecular weight (average) calculated: 4901.4 Da
  • LCMS_A: Rt=6.3 min; found [M+3H]3+ 1634.6, [M+4H]4+ 1226.1
    • Example 2: In Vitro Functional Potency (CRE Luciferase; Whole Cells)
  • The purpose of this example is to test the functional activity, or potency, of the compounds in vitro at the human GLP-1 and GIP receptors. The in vitro functional potency is the measure of target receptor activation in a whole cell assay. The potencies of derivatives of Example 1 were determined as described below. Human GLP-1(7-37) and human GIP were included in appropriate assays for comparison.
    • Principle
  • In vitro functional potency was determined by measuring the response of the target receptor in a reporter gene assay in individual cell lines. The assay was performed in stably transfected BHK cell lines that expresses one of the following G-protein coupled receptors: human GLP-1 receptor or human GIP receptor; and where each cell line contains the DNA for the cAMP response element (CRE) coupled to a promoter and the gene for firefly luciferase (CRE luciferase). When the respective receptor is activated, it results in the production of cAMP, which in turn results in expression of the luciferase protein. When assay incubation is completed, luciferase substrate (luciferin) is added resulting in the enzymatic conversion of luciferin to oxyluciferin and producing bioluminescence. The luminescence is measured as the readout for the assay.
    • Cell Culture and Preparation
  • The cells lines used in these assays were BHK cells with BHKTS13 as a parent cell line. The cell lines were derived from a clone containing the CRE luciferase element and were established by further transfection with the respective human receptor to obtain the relevant cell line: BHK CRE luc2P hGLP-1R or BHK CRE luc2P hGIPR. The cells were cultured at 37° C. with 5% CO2 in Cell Culture Medium. They were aliquoted and stored in liquid nitrogen. The cells were kept in continuous culture and were seeded out the day before each assay.
    • Materials
  • The following chemicals were used in the assay: Pluronic F-68 10% (Gibco 2404), human serum albumin (HSA; Sigma A9511), 10% fetal bovine serum (FBS; Invitrogen 16140-071), chicken egg white ovalbumin (Sigma A5503), DMEM w/o phenol red (Gibco 21063-029), DMEM (Gibco 12430-054), 1 M Hepes (Gibco 15630), Glutamax 100× (Gibco 35050), G418 (Invitrogen 10131-027), hygromycin (Invitrogen 10687-010), and steadylite plus (PerkinElmer 6016757).
    • Buffers
  • GLP-1R Cell Culture Medium consisted of DMEM medium with 10% FBS, 500 μg/mL G418, and 300 μg/mL hygromycin. GIPR Cell Culture Medium consisted of DMEM medium with 10% FBS, 400 μg/mL G418, and 300 μg/mL hygromycin. Assay Buffer consisted of DMEM w/o phenol red, 10 mM Hepes, 1× Glutamax. 1% ovalbumin, and 0.1% Pluronic F-68 with the addition of HSA at twice the final assay concentration. The Assay Buffer was mixed 1:1 with an equal volume of the test compound in Assay Buffer to give the final assay concentration of HSA.
  • Procedure
      • 1) Cells were plated at 5000 cells/well and incubated overnight in the assay plate.
      • 2) Cells were washed once in DPBS.
      • 3) Stocks of the test compounds and reference compounds in concentrations ranging from 100-300 pM were diluted 1:150 in Assay Buffer. Compounds were then diluted 1:10 in column 1 of a 96 deep well dilution plate and then carried across the row creating a 3.5 fold, 12 point dilution curve.
      • 4) Assay Buffer (50 μl aliquot) with or without HSA was added to each well in the assay plate.
      • 5) A 50 μl aliquot of compound or blank was transferred from the dilution plate to the assay plate containing the Assay Buffer with or without HSA.
      • 6) The assay plate was incubated for 3 h in a 5% CO2 incubator at 37° C.
      • 7) The cells were washed once with DPBS.
      • 8) A 100 μl aliquot of DPBS was added to each well of the assay plate.
      • 9) A 100 μl aliquot of steadylite plus reagent (light sensitive) was added to each well of the assay plate.
      • 10) Each assay plate was covered with aluminum foil to protect it from light and shaken at 250 RPM for 30 min at room temperature.
      • 11) Each assay plate was read in a microtiter plate reader.
    Calculations and Results
  • The data from the microtiter plate reader was first regressed in an Excel in order to calculate the x-axis, log scale concentrations based on the individual test compound's stock concentration and the dilutions of the assay. This data was then transferred to GraphPad Prism software for graphing and statistical analysis. The software performs a non-linear regression (log(agonist) vs response). EC50 values which were calculated by the software and reported in pM are shown in Tables 1-3 below. A minimum of two replicates was measured for each sample. The reported values are averages of the replicates.
  • TABLE 1
    Functional potencies at human GLP-1R and
    GIPR in the presence of 0% and 1% HSA.
    hGLP-1R, hGLP-1R, hGIPR, hGIPR,
    CRE Luc CRE Luc CRE Luc CRE Luc
    Compound 0% HSA 1% HSA 0% HSA 1% HSA
    No. EC50 (pM) EC50 (pM) EC50 (pM) EC50 (pM)
    hGLP-1(7-37) 8.4 6.7 nd nd
    hGIP nd nd 11.3 6.4
    1 7.8 1659.0 2.8 172.5
    2 6.0 899.7 3.8 275.4
    3 8.5 626.3 6.9 229.2
    4 6.6 484.3 8.5 293.8
    5 9.4 624.8 14.2 362.4
    6 3.4 242.7 18.5 434.0
    7 4.2 513.2 28.7 686.8
    8 2.3 82.1 6.7 191.1
    9 3.8 278.8 10.8 508.2
    10 3.9 939.9 11.3 1745.1
    11 3.3 132.3 9.9 450.2
    37 2.7 94.6 11.2 297.8
    12 4.0 54.4 9.0 71.5
    13 7.4 204.1 13.9 257.2
    14 5.4 306.2 11.6 580.1
    15 5.0 129.7 7.1 137.5
    38 3.1 258.9 12.4 815.1
    16 3.1 321.1 13.4 803.8
    17 5.2 256.6 34.9 1319.0
    18 19.7 226.2 20.9 285.1
    19 8.6 364.8 6.5 275.4
    20 4.2 256.0 7.1 247.4
    21 5.7 118.2 5.4 130.9
    22 2.8 170.5 6.2 168.9
    23 4.1 117.8 6.7 134.3
    24 12.1 490.2 3.9 115.1
    25 15.5 740.2 7.2 263.0
    26 7.4 594.6 4.9 153.0
    39 8.2 135.4 28.4 365.2
    27 4.6 127.0 6.3 131.8
    28 6.2 139.1 6.6 86.5
    29 16.8 378.5 3.8 101.7
    30 7.3 267.5 3.2 185.0
    41 1.2 31.4 4.9 79.3
    42 2.3 83.5 5.9 305.7
    40 6.4 333.6 9.5 500.6
    31 4.2 202.0 4.7 188.5
    32 5.0 981.9 7.1 678.7
    43 4.0 359.5 5.6 444.5
    44 4.2 240.9 5.7 365.3
    33 14.8 360.7 2.9 102.8
    34 6.0 186.4 8.3 212.8
    35 3.0 412.6 5.2 303.0
    36 4.7 413.8 5.5 356.5
    45 3.9 1580.0 3.8 1220.0
    46 1.5 110.8 1.8 97.0
    47 2.1 154.5 3.1 155.7
    nd = not determined.
  • The compounds of the present invention display potent functional activation of the human GLP-1R and human GIPR receptors under the given conditions. Alteration of the peptide and/or the substituent resulted in unpredictable changes in the measured potencies at each of the two receptors, as well as the ratio of potencies between the two receptors, for each compound.
    • Example 3: Pharmacokinetic Study in Minipigs
  • The purpose of this example is to determine the half-life in vivo of the derivatives of the present invention after i.v. administration to minipigs, i.e. the prolongation of their time in the body and thereby their time of action. This is done in a pharmacokinetic (PK) study, where the terminal half-life of the derivative in question is determined. By terminal half-life is generally meant the period of time it takes to halve a certain plasma concentration, measured after the initial distribution phase.
    • Study
  • Female Gottingen minipigs were obtained from Ellegaard Gottingen Minipigs (Dalmose, Denmark) approximately 7-14 months of age and weighing from approximately 16-35 kg were used in the studies. The minipigs were housed individually and fed restrictedly once daily with SDS minipig diet (Special Diets Services, Essex, UK).
  • After at 3 weeks of acclimatisation two permanent central venous catheters were implanted in vena cava caudalis in each animal. The animals were allowed 1 week recovery after the surgery, and were then used for repeated pharmacokinetic studies with a suitable wash-out period between successive derivative dosing.
  • The animals were fasted for approximately 18 hours before dosing and from 0 to 4 hours after dosing but had ad libitum access to water during the whole period.
  • The sodium salts of compounds of Examples 1 were dissolved to a concentration of 20-40 nmol/mL in a buffer containing 0.007% polysorbate 20, 50 mM sodium phosphate, 70 mM sodium chloride, pH 7.4. Intravenous injections (the volume corresponding to usually 1.5-2 nmol/kg, for example 0.1 mL/kg) of the compounds were given through one catheter, and blood was sampled at predefined time points for up to 14 days post dosing (preferably through the other catheter). Blood samples (for example 0.8 mL) were collected in 8 mM EDTA buffer and then centrifuged at 4° C. and 1942 g for 10 minutes.
    • Sampling and Analysis
  • Plasma was pipetted into Micronic tubes on dry ice and kept at −20° C. until analysed for plasma concentration of the compounds using ELISA, or a similar antibody-based assay, or LCMS. Individual plasma concentration-time profiles were analysed by a non-compartmental model in Phoenix WinNonLin ver. 6.4. (Pharsight Inc., Mountain View, Calif., USA), and the resulting terminal half-lives (harmonic mean) determined.
  • Results
  • TABLE 2
    Terminal half-life as measured after i.v. administration to minipigs
    Compound No. t1/2 (h)
    15 36
    28 35
    29 68
    31 49
  • The tested compounds of the present invention have very long half-lives as compared to the half-lives of hGLP-1 and hGIP measured in man to be approximately 2-4 min and 5-7 min, respectively (Meier et al., Diabetes, 2004, 53(3): 654-662). The measured half-lives in minipigs predict half-lives in humans sufficient for at least once-weekly administration via liquid injection or at least once-daily administration via oral tablet. Unexpectedly, alterations to the peptide sequence led to appreciable differences in half-lives between co-agonists tested herein even though these co-agonists incorporate the same substituent.
    • Example 5: Pharmacokinetic Study in Dogs
  • The purpose of this example is to determine the half-life and plasma exposure in vivo of the compounds of the present invention after p.o. administration to beagle dogs, i.e. the terminal half-life and concentration of test substance that reaches circulation with time. This is done in a pharmacokinetic (PK) study, where these parameters of the compound in question are determined. By terminal half-life is generally meant the period of time it takes to halve a certain plasma concentration, measured after the initial distribution phase.
  • Preparation of Tablet Compositions
  • Tablet compositions comprising the test substance and SNAC (sodium N-(8-(2-hydroxybenzoyl)amino)caprylate) were prepared according to methods known to the person skilled in the art by mixing test substance with roller compacted SNAC and magnesium stearate as e.g. described in WO 2019/149880. The amount of SNAC in the tablet composition was 100-300 mg, the amount of magnesium stearate in the tablet composition was 7.7 mg, and the target amount of each test substance in the tablet composition was 3-4 mg.
  • Animals, Dosing, and Sampling
  • Male beagle dogs, 1-7 years of age and weighing 9-17 kg during the study period, were included in the study. The dogs were dosed in a fasting state. The dogs were group housed in pens (12 hours light: 12 hours dark), and fed individually and restrictedly once daily with Royal Canin Medium Adult dog food (Royal Canin Products, China Branch, or Brogaarden A/S, Denmark). The dogs were used for repeated PK studies with a suitable wash-out period between successive dosing. An appropriate acclimatization period was given prior to initiation of the first PK study. All handling, dosing, and blood sampling of the animals were performed by trained and skilled staff. Before the studies, the dogs were fasted overnight and from 0 to 4 hours after dosing. The dogs were restricted to water 1 hour before dosing until 4 hours after dosing, but otherwise had ad libitum access to water during the whole period.
  • The compositions were administered by a single oral dosing to the dogs in groups of 6-8 dogs. The tablets were administered in the following manner: 10 min prior to tablet administration, the dogs may be dosed subcutaneously with approximately 3 nmol/kg of SEQ ID NO: 48, then tablets were placed in the back of the mouth of the dog to prevent chewing. The mouth was then closed, and 10 mL of tap water was given by syringe or gavage to facilitate swallowing of the tablet.
  • One blood sample was drawn before dosing, and additional samples were drawn at predefined time points after dosing for up to 240 hours, such as up to 10 hours, to adequately cover the full plasma concentration-time absorption profile of the test substance. For each blood sample time point, approximately 0.8 mL of whole blood was collected in a 1.5 mL EDTA-coated tube, which was gently turned to mix the sample with EDTA. Blood samples were collected in EDTA buffer (8 mM) and then centrifuged at 4° C. 2000 g for 10 minutes. Plasma was pipetted into Micronic tubes on dry ice, and kept at −20° C. or lower until analysis. Blood samples were taken as appropriate, for example from a venflon in the cephalic vein in the front leg for the first 2 hours and then with syringe from the jugular vein for the rest of the time points. The first few drops were allowed to drain from the venflon to avoid heparin saline from the venflon in the sample.
  • All blood samples were collected into test tubes containing EDTA for stabilisation and kept on ice until centrifugation. Plasma was separated from whole blood by centrifugation and the plasma was stored at −20° C. or lower until analysis.
  • Analysis and Calculations
  • The plasma was analysed for test substance using LC-MS (Liquid Chromatography-Mass Spectrometry) as known to the person skilled in the art. The system consisted of either: a Thermo Fisher QExactive mass spectrometer equipped with a 10-valve interface module TurboFlow system, CTC HTS PAL autosampler, Accela 1250 pumps, and Hot Pocket column oven; or a Thermo Fisher QExactive Plus mass spectrometer equipped with a valve interface module TurboFlow system, TriPlus RSI autosampler, Dionex UltiMate 3000 pumps, and Hot Pocket column oven. RP-HPLC separation was achieved using a linear gradient of 1:1 acetonitrile/methanol in 1% aqueous formic acid using either: a Phenomenex Onyx Monolithic C18 column (50×2.0 mm) and a flow rate of 0.8 mL/min at 30° C.; or an Agilent Poroshell 120 SB-C18 column (50×2.1 mm, 2.7 μm) at a flow rate of 0.4 mL/min at 60° C. The mass spectrometer was operated in either positive ionization SIM mode or positive ionization PRM mode.
  • For each individual animal, a plasma concentration-time profile was analysed by a non-compartmental model in Pharsight Phoenix WinNonLin ver. 6.4 software or other relevant software for PK analysis, and the resulting terminal half-life (t1/2), maximum plasma concentration per dose (Cmax/D), time for maximum plasma concentration (tmax), and area under the curve to infinity per dose (AUC/D) were determined. Summary statistics of pharmacokinetic results were presented as median (for tmax), hormonic mean (t1/2), or arithmetic mean (Cmax, AUC).
  • Results
  • TABLE 3
    Pharmacokinetic parameters following oral dosing of tablet
    compositions of test substance and SNAC to Beagle dogs.
    Target
    amount
    Com- Amount of test Cmax/ AUC/
    pound of SNAC substance Tmax t1/2 Dose Dose
    No. (mg) (mg) (h) (h) (kg/L) (kg*h/L)
    9 100 4 2.0 50 0.24 12.1
    10 100 4 1.0 36 0.20 8.4
    11 100 4 1.4 34 0.19 7.1
    13 100 3 1.5 60 0.29 14.8
    15 100 3 1.5 59 0.24 11.9
    15 300 3 2.0 46 0.28 11.6
    16 100 3 1.3 47 0.21 8.6
    20 100 3 2.0 56 0.21 10.8
    24 300 3 1.8 74 0.29 16.4
    25 300 3 1.8 43 0.30 15.2
    26 300 3 1.2*  70* 0.49* 27.4*
    28 300 3 1.3**  67** 0.36** 18.6**
    29 300 3 1.2**  69** 0.26** 16.6**
    30 300 3 0.8 81 0.24 6.5
    40 300 3 2.0 61 0.48 27.0
    31 300 3 1.3**  56** 0.35** 17.9**
    32 300 3 1.8*  80* 0.45* 25.3*
    43 300 3 1.5 131  0.22 21.4
    *= averaged data from two experiments under same formulation conditions;
    **= averaged data from three experiments under same formulation conditions.
  • The tested compounds of the present invention demonstrate oral bioavailability in this model, as concentrations of the compound in plasma were detected (Cmax/D>0 and AUC/D>0) following oral administration. Furthermore, the tested compounds of the present invention further have very long half-lives as compared to the half-lives of hGLP-1 and hGIP measured in man to be approximately 2-4 min and 5-7 min, respectively (Meier et al., Diabetes, 2004, 53(3): 654-662). Alterations to the peptide sequence led to unpredictable differences in t1/2, Cmax/D and AUC/D between co-agonists even when the same substituent was incorporated. Additionally, an unexpectedly large difference in t1/2 was observed depending on the position of the amino acid attached to the substituent, such as eg., Compound No. 43 compared to all other compounds tested herein.
  • While certain features of the invention have been illustrated and described herein, many modifications, substitutions, changes, and equivalents will now occur to those of ordinary skill in the art. It is, therefore, to be understood that the appended embodiments are intended to cover all such modifications and changes as fall within the true spirit of the invention.

Claims (1)

1. A compound comprising a peptide and a substituent, wherein the compound is
Figure US20230120597A1-20230420-C00117
wherein the amino acid sequence of the peptide is SEQ ID NO:25;
or a pharmaceutically acceptable salt thereof.
US17/980,990 2020-07-22 2022-11-04 Co-agonists at glp-1 and gip receptors suitable for oral delivery Abandoned US20230120597A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US17/980,990 US20230120597A1 (en) 2020-07-22 2022-11-04 Co-agonists at glp-1 and gip receptors suitable for oral delivery

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202063055026P 2020-07-22 2020-07-22
EP20192414.9 2020-08-24
EP20192414 2020-08-24
US202163156988P 2021-03-05 2021-03-05
PCT/EP2021/070485 WO2022018186A1 (en) 2020-07-22 2021-07-22 Co-agonists at glp-1 and gip receptors suitable for oral delivery
US17/574,079 US11779648B2 (en) 2020-07-22 2022-01-12 Co-agonists at GLP-1 and GIP receptors suitable for oral delivery
US17/980,990 US20230120597A1 (en) 2020-07-22 2022-11-04 Co-agonists at glp-1 and gip receptors suitable for oral delivery

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US17/574,079 Continuation US11779648B2 (en) 2020-07-22 2022-01-12 Co-agonists at GLP-1 and GIP receptors suitable for oral delivery

Publications (1)

Publication Number Publication Date
US20230120597A1 true US20230120597A1 (en) 2023-04-20

Family

ID=77179985

Family Applications (4)

Application Number Title Priority Date Filing Date
US18/017,041 Pending US20230272029A1 (en) 2020-07-22 2021-07-22 Co-agonists at glp-1 and gip receptors suitable for oral delivery
US17/383,192 Abandoned US20220177538A1 (en) 2020-07-22 2021-07-22 Co-agonists at glp-1 and gip receptors suitable for oral delivery
US17/574,079 Active US11779648B2 (en) 2020-07-22 2022-01-12 Co-agonists at GLP-1 and GIP receptors suitable for oral delivery
US17/980,990 Abandoned US20230120597A1 (en) 2020-07-22 2022-11-04 Co-agonists at glp-1 and gip receptors suitable for oral delivery

Family Applications Before (3)

Application Number Title Priority Date Filing Date
US18/017,041 Pending US20230272029A1 (en) 2020-07-22 2021-07-22 Co-agonists at glp-1 and gip receptors suitable for oral delivery
US17/383,192 Abandoned US20220177538A1 (en) 2020-07-22 2021-07-22 Co-agonists at glp-1 and gip receptors suitable for oral delivery
US17/574,079 Active US11779648B2 (en) 2020-07-22 2022-01-12 Co-agonists at GLP-1 and GIP receptors suitable for oral delivery

Country Status (14)

Country Link
US (4) US20230272029A1 (en)
EP (1) EP4185607A1 (en)
JP (1) JP2023534131A (en)
KR (2) KR20230029480A (en)
CN (1) CN116157143A (en)
AU (1) AU2021312323A1 (en)
BR (1) BR112023000270A2 (en)
CA (1) CA3184717A1 (en)
CL (1) CL2023000087A1 (en)
CO (1) CO2023000097A2 (en)
IL (1) IL299701A (en)
MX (1) MX2023000303A (en)
TW (2) TW202315883A (en)
WO (1) WO2022018186A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11840560B2 (en) 2022-01-20 2023-12-12 Novo Nordisk A/S Prodrugs and uses thereof

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023534131A (en) 2020-07-22 2023-08-08 ノヴォ ノルディスク アー／エス GLP-1 Receptor and GIP Receptor Co-Agonists Suitable for Oral Delivery
WO2023012263A1 (en) 2021-08-04 2023-02-09 Novo Nordisk A/S Solid oral peptide formulations
WO2024012472A1 (en) * 2022-07-13 2024-01-18 杭州中美华东制药有限公司 Glp-1/gip dual agonist, and preparation method therefor and use thereof
WO2024110614A1 (en) 2022-11-25 2024-05-30 Novo Nordisk A/S Oral administration of peptide therapeutics, such as glp-1

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9062124B2 (en) 2008-06-17 2015-06-23 Indiana University Research And Technology Corporation GIP-based mixed agonists for treatment of metabolic disorders and obesity
CN102300580A (en) 2008-12-19 2011-12-28 印第安纳大学研究及科技有限公司 Dipeptide linked medicinal agents
TWI489992B (en) 2008-12-19 2015-07-01 印地安那大學研究及技術公司 Amide based glucagon superfamily peptide prodrugs
MX2011013625A (en) 2009-06-16 2012-01-20 Univ Indiana Res & Tech Corp Gip receptor-active glucagon compounds.
WO2011080102A2 (en) 2009-12-16 2011-07-07 Novo Nordisk A/S Glp-1 analogues and derivatives
WO2011163012A2 (en) 2010-06-24 2011-12-29 Indiana University Research And Technology Corporation Amide based glucagon superfamily peptide prodrugs
RU2013102991A (en) 2010-06-24 2014-08-10 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн DIPEPTIDE-related MEDICINES
HUE036066T2 (en) 2010-12-16 2018-06-28 Novo Nordisk As Solid compositions comprising a glp-1 agonist and a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid
PE20140186A1 (en) 2010-12-22 2014-02-13 Univ Indiana Res & Tech Corp GLUCAGON ANALOGS PRESENTING GIP RECEPTOR ACTIVITY
AR084558A1 (en) * 2010-12-22 2013-05-22 Marcadia Biotech METHODS TO TREAT METABOLIC DISORDERS AND OBESITY WITH ACTIVE GLUCAGON-BASED PEPTIDES FOR THE GLUCOSE DEPENDENT INSULINOTROPIC PEPTIDE RECEPTOR (GIP) / PEPTIDO-1 SIMILAR TO GLUCAGON (GLP-1)
JP5914641B2 (en) 2011-06-10 2016-05-11 ベイジン・ハンミ・ファーマシューティカル・カンパニー・リミテッドＢｅｉｊｉｎｇ Ｈａｎｍｉ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏ．， Ｌｔｄ． Glucose-dependent insulinotropic polypeptide analogs, pharmaceutical compositions and uses thereof
EP2827845B1 (en) * 2012-03-22 2018-12-26 Novo Nordisk A/S Compositions comprising a delivery agent and preparation thereof
CN104470948B (en) 2012-05-03 2018-06-15 西兰制药公司 GIP-GLP-1 double agonists compound and method
EP2863895B1 (en) 2012-06-20 2021-04-14 Novo Nordisk A/S Tablet formulation comprising a peptide and a delivery agent
CA2877127A1 (en) 2012-06-21 2013-12-27 Indiana University Research And Technology Corporation Analogs of glucagon exhibiting gip receptor activity
JP2016503771A (en) 2012-12-21 2016-02-08 サノフイ Exendin-4 derivative
WO2014152460A2 (en) 2013-03-15 2014-09-25 Indiana University Research And Technology Corporation Prodrugs with prolonged action
RU2671406C2 (en) * 2013-05-02 2018-10-31 Ново Нордиск А/С Oral dosing of glucagon-like peptide-1 compounds
ES2900744T3 (en) 2013-05-28 2022-03-18 Takeda Pharmaceuticals Co peptide compound
EP3033355A1 (en) 2013-08-16 2016-06-22 Medimmune Limited Gip and glp-1 receptor dual-agonists for the treatment of diabetes
WO2015035419A1 (en) 2013-09-09 2015-03-12 Hoffmann-La Roche Inc. Dosages of gip/glp-1 co-agonist peptides for human administration
WO2015067715A2 (en) * 2013-11-06 2015-05-14 Zealand Pharma A/S Gip-glp-1 dual agonist compounds and methods
WO2015086729A1 (en) 2013-12-13 2015-06-18 Sanofi Dual glp-1/gip receptor agonists
EP3080150B1 (en) 2013-12-13 2018-08-01 Sanofi Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
TW201625670A (en) * 2014-04-07 2016-07-16 賽諾菲公司 Dual GLP-1/glucagon receptor agonists derived from EXENDIN-4
GB2528436A (en) 2014-07-15 2016-01-27 Lancaster Univ Business Entpr Ltd Treatment of neurological diseases
ES2947409T3 (en) 2014-09-24 2023-08-08 Univ Indiana Res & Tech Corp Lipid amide-based insulin prodrugs
WO2016077220A1 (en) 2014-11-10 2016-05-19 Mb2 Llc Gip/glp-1 co-agonist peptides for human administration
JP2018012644A (en) 2014-11-26 2018-01-25 武田薬品工業株式会社 Peptide compound
JOP20200119A1 (en) * 2015-01-09 2017-06-16 Lilly Co Eli Gip and glp-1 co-agonist compounds
WO2016131893A1 (en) 2015-02-18 2016-08-25 Medimmune Limited Incretin fusion polypeptides
US20170112897A1 (en) 2015-10-23 2017-04-27 Cedars-Sinai Medical Center Methods for treating brain insulin resistance
US10501516B2 (en) 2016-05-24 2019-12-10 Takeda Pharmaceutical Company Limited Peptide compound
GB201620611D0 (en) 2016-12-05 2017-01-18 Univ Of Lancaster Treatment of neurological diseases
JOP20180028A1 (en) 2017-03-31 2019-01-30 Takeda Pharmaceuticals Co Peptide compound
PE20210453A1 (en) 2018-02-02 2021-03-08 Novo Nordisk As SOLID COMPOSITIONS INCLUDING A GLP-1 AGONIST, A SALT OF N- (8- (2-HYDROXIBENZOIL) AMINO) CAPRYLIC ACID AND A LUBRICANT
EP3788063B1 (en) 2018-05-04 2023-08-09 Novo Nordisk A/S Gip derivatives and uses thereof
JP2021533094A (en) 2018-07-23 2021-12-02 イーライ リリー アンド カンパニー Method of using GIP / GLP1 coagonist for therapy
US11084861B2 (en) 2018-07-23 2021-08-10 Eli Lilly And Company GIP/GLP1 co-agonist compounds
IL308674A (en) 2018-07-23 2024-01-01 Lilly Co Eli Method of using a gip/glp1 co-agonist for diabetes
WO2020207477A1 (en) * 2019-04-11 2020-10-15 江苏豪森药业集团有限公司 Glp-1 and gip receptor dual agonist compounds and use thereof
CN110642935A (en) 2019-09-25 2020-01-03 成都奥达生物科技有限公司 Tirapapotide analogue
CN110684082B (en) 2019-10-08 2021-12-10 江苏诺泰澳赛诺生物制药股份有限公司 GIP and GLP-1 dual-agonist polypeptide compound, pharmaceutically acceptable salt and application
JP2023534131A (en) 2020-07-22 2023-08-08 ノヴォ ノルディスク アー／エス GLP-1 Receptor and GIP Receptor Co-Agonists Suitable for Oral Delivery

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11840560B2 (en) 2022-01-20 2023-12-12 Novo Nordisk A/S Prodrugs and uses thereof

Also Published As

Publication number Publication date
KR20220012840A (en) 2022-02-04
CA3184717A1 (en) 2022-01-27
JP2023534131A (en) 2023-08-08
TWI801942B (en) 2023-05-11
CL2023000087A1 (en) 2023-07-07
US20220125940A1 (en) 2022-04-28
TW202315883A (en) 2023-04-16
KR102446310B1 (en) 2022-09-23
US20230272029A1 (en) 2023-08-31
TW202208411A (en) 2022-03-01
US20220177538A1 (en) 2022-06-09
MX2023000303A (en) 2023-02-09
CN116157143A (en) 2023-05-23
CO2023000097A2 (en) 2023-03-27
US11779648B2 (en) 2023-10-10
AU2021312323A1 (en) 2023-02-02
WO2022018186A1 (en) 2022-01-27
IL299701A (en) 2023-03-01
EP4185607A1 (en) 2023-05-31
BR112023000270A2 (en) 2023-01-31
KR20230029480A (en) 2023-03-03

Similar Documents

Publication Publication Date Title
US10604555B2 (en) GIP derivatives and uses thereof
US11779648B2 (en) Co-agonists at GLP-1 and GIP receptors suitable for oral delivery
US20230391845A1 (en) Glp-1, gip and glucagon receptor triple agonists
US20230346961A1 (en) Glp-1 and gip receptor co-agonists
US11840560B2 (en) Prodrugs and uses thereof
CN116457002A (en) GLP-1, GIP and glucagon receptor triple agonists

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: EXPRESSLY ABANDONED -- DURING EXAMINATION